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Abstract 
Marnisa Sricholpech 
Mechanisms and Functions of Collagen Glycosylations in Bone 
(Under the direction of Professor Mitsuo Yamauchi) 
 
O-linked glycosylation of hydroxylysine (Hyl) is one of the unique post-translational 
modifications found in collagens and collagen-like proteins. In type I collagen, some of the 
helical Hyl residues are galactosylated, forming galactosylhydroxylysine (G-Hyl) which can 
be further glucosylated into glucosylgalactosylhydroxylysine (GG-Hyl). The critical 
importance of these glycosylated Hyl residues was implicated since alterations in their levels 
were associated with several human connective disorders. To date, the multifunctional 
enzyme, lysyl hydroxylase 3 (LH3), has been shown to be the major glucosyltransferase 
enzyme, while its galactosyltransferase function is still debatable. For bone type I collagen, 
little is known about the regulatory mechanisms and the significance of Hyl glycosylation. 
Therefore, in this study, we have aimed to elucidate the formation mechanism and functions 
of the glycosylated Hyl in type I collagen by utilizing mouse osteoblast (MC3T3-E1 (MC) 
cells) culture system. Short hairpin RNA technology was employed to stably suppress the 
expression of LH3 gene (Plod3) and generate single cell-derived clones (Sh clones). 
Characterization of type I collagen, synthesized by the Sh clones, showed significant level 
decrease of GG-Hyl with concomitant increase of G-Hyl while total Hyl remained 
unchanged, thus indicating the major function of LH3 in G-Hyl glucosylation (Study I). By 
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mass spectrometry, specific molecular loci and forms of glycosylation have been identified at 
residues α1-87, α1-174 and α2-173. In addition, the effect of lowered LH3-mediated 
glucosylation was observed in the formation and maturation of intermolecular cross-links, 
collagen matrix organization and mineralization (Study II). Most recently, novel collagen 
galactosyltransferase enzymes, glycosyltransferase 25 domain 1 and 2 (GLT25D1 and D2), 
have been discovered and characterized. We have shown in study I that Glt25d1 is the only 
isoform expressed in MC cells. By suppressing Glt25d1, the type I collagen synthesized 
showed significantly lower levels of both G-Hyl and GG-Hyl (Study III). In conclusion, the 
results from all these studies clearly indicate that for bone type I collagen, Hyl 
galactosylation is modulated by Glt25d1 and subsequent glucosylation by LH3. Moreover, 
the glucose units in the GG-Hyl residues appeared to play essential roles in the formation of 
normal collagen template for the mineralization process. 
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Chapter 1 
 
Review of Literature 
 
1.1 Collagen superfamily 
Collagens are a family of extracellular proteins which mainly serve as the structural 
basis of all tissues. In the vertebrates, there are now at least 29 collagen types, encoded by 
more than 40 different genes, which can be categorized into families based on their 
supramolecular assemblies and other specific features. The major categories include fibrillar 
collagens, fibril-associated collagens with interrupted triple helices (FACITs), network-
forming collagens, transmembranous collagens and others (1-2). To date, increasing numbers 
of proteins, which contain triple-helical collagenous domains (e.g. C1q, adiponectin, 
collectins, ficolins, surfactant protein A and D, acetylcholinesterase, macrophage scavenger 
receptors, ectodysplasin and etc.) (3-5), have been discovered and many of those are involved 
in innate immunity. 
 Fibrillar collagens (type I, II, III, V, XI, XXIV and XXVII) constitutes the group of 
collagens which form fibrils with unique repeated banding pattern, called D-periodicity 
which arise from the ordered staggering of the collagen molecules. Each molecule is formed 
from three polypeptide chains named α chains, either in a homotrimeric or a heterotrimeric 
fashion, depending on the collagen type and some existing variants. Another common 
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characteristic of fibrillar collagens is the long triple helical region with unique Gly-X-Y 
triplet repeats, flanked by the short non-helical part called telopeptides. Among the fibrillar 
collagens, type I collagen is the most abundant collagen found in various connective tissues 
such as skin, bone, tendon, dentin and etc and has been shown to portray critical roles for 
maintaining the integrity and elasticity of the tissues.(3) 
 
1.2 Type I collagen biosynthesis 
Type I collagen, one of the fibrillar collagens, is formed from the syntheses of 
procollagen α1 and α2 chains, encoded by COL1A1 and COL1A2 genes respectively, in the 
endoplasmic reticulum (ER). At which time they undergo extensive co- and post-translational 
modifications including the unique hydroxylation of proline (Pro) and lysine (Lys) residues, 
subsequent O-linked glycosylation of specific hydroxylysine (Hyl) residues and asparagine-
linked glycosylations. Proline residues in the Y position of the Gly-X-Y triplet are mostly 
hydroxylated by prolyl-4-hydroxylase (P4H), while some of those at the X position are 
hydroxylated by prolyl-3 hydroxylase (P3H). Hydroxyproline (Hyp) has been shown to be 
the key to the triple-helix stabilization. Lysine hydroxylation and its subsequent 
glycosylation will be reviewed in detail in section 1.6.  The modified procollagen chains, two 
α1 and one α2, further associate by forming disulfide bonds at the C-propeptide region, and 
then fold into triple helical conformation towards the N-terminal region. Each of the 
polypeptide chains contains unique repetitive amino acid sequences, glycine-proline-X (Gly-
Pro-X) or glycine-X-hydroxyproline (Gly-X-Hyp), which allow the folding of the 3 chains in 
to triple helical conformation where the Gly residues are located inside the molecule and the 
other amino acids facing outwards probably involving in the intermolecular interactions. In  
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this process, several proteins act as chaperones in trimerization and folding of the α chains 
either by selectively binding to the unfolded procollagen α chains to prevent premature triple 
helix formation (e.g. P4H, protein disulphide isomerase (PDI), Bip/Grp78, Grp94, and 
immunophillins), or bind to the completely folded collagen molecule to stabilize the triple 
helix and possibly prevent premature aggregation of the procollagen molecules in the ER.  
 
Figure 1.1) Schematic for the biosynthesis of type I collagen. The intracellular events include 
extensive post-translational modifications such as hydroxylation, glycosylation (both O- and N-
linked), association of pro α chains and folding into triple helical molecule from the C- to N-terminus. 
The extracellular events involve the removal of both N- and C-propeptides, self assembly of collagen 
molecules into a fibril, enzymatic oxidative deamination of the telopeptidyl Lys and Hyl residues by 
LOX and subsequent intra- and intermolecular cross-linking. The collagen molecules are packed in 
parallel and are longitudinally staggered with respect to one another by some multiple of axial repeat 
distance, D (~67nm). This packing arrangement creates repeated regions of high and low packing 
density , i.e. overlap and hole regions, respectively, showing a characteristic banding pattern of 
collagen fibril seen at utltrastructural level. LH: lysyl hydroxylase, PH: prolyl hydroxylase, GGT: 
galactosylhydroxylysyl glucosyltransferase, GT: hydroxylysyl galactosyltransferase, OTC: 
oligsaccharyl transferase complex, PDI: protein disulfide isomerase, PPI: peptidyl-prolyl cis-trans 
isomerase, Hsp: heat shock protein, Bip: binding proteins, GRP: glucose-regulated protein, PNP: 
procollagen-N-proteinase, PCP: procollagen-C-proteinase, BMP: bone morphogenetic protein, LOX: 
lysyl oxidase, Solid line: pro α1 chain, Dotted line: pro α2 chain. Diagram reproduced with 
permission from Yamauchi M. 
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The procollagen molecules are then transported through the Golgi apparatus and secreted into 
the extracellular matrix, where the N- and C-propeptides are cleaved by their respective 
procollagen N-proteinase and procollagen C-proteinase, after which, the collagen molecules 
would spontaneously self-assemble in ordered stagger arrays. Each molecule would overlap 
each other by 234 residues, forming the 67 nm D-period repetitive regions of collagen which 
consist of the unique hole and overlap zones in the collagen fibrils (Figure 1.1) (reviewed in 
(3,6).  
 
1.3 Type I collagen fibrillogenesis 
Formation of type I collagen fibrils in physiological condition occurs as a 
spontaneous process. The processed collagen molecules self assemble and align by the 
interactions of the charge and hydrophobic regions in the helical region (7). Besides, the 
factors that could regulate collagen fibrillogenesis include the following: 
 The levels of post-translational modifications e.g. Lys hydroxylation and 
glycosylation. Collagen with higher levels of modification is associated with the 
formation of fibrils with smaller diameter. (8-11). 
 Collagen-binding small leucine-rich proteoglycans (SLRPs), containing the unique 
leucine-rich repeats, flanked by cysteine-rich clusters and attachments of 
glycosaminoglycan (GAG) chains, are shown to control collagen fibril formation (12-
14). DCN is localized in close association with collagen fibers and is a well-
characterized regulator of collagen fibrillogenesis (15). DCN knockout (KO) mice 
developed lax and fragile skin that exhibited loosely packed type I collagen fibrils, 
with larger and irregular diameter probably due to the uncontrolled lateral fusion of 
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fibrils (16). By manipulating the expression level of DCN in the mouse osteoblast cell 
culture system, we also have observed similar abnormalities of the collagen fibrils 
(17).  
 Type III and V collagen have been shown to be the regulators of type I collagen 
fibrils lateral growth. Heterotypic fibrils formed from those three different collagen 
types can be found in skin.  However, their presence in bone is considered low (18). 
 Interestingly, some extracellular matrix proteins have been found to promote collagen 
fibril formation in vitro, It was speculated that the protein-collagen interaction may 
stabilize the initial aggregation of the collagen molecules for further fibril growth 
(reviewed in (3)). 
 
1.4 Collagen cross-links in mineralized tissues 
The collagen molecules, spontaneously aggregated into fibrils, are further stabilized 
by the final step of post-translational modification, the formation of intra and intermolecular 
cross-links.  They are initiated by the generation of aldehydes at specific Lys or Hyl residues 
in the telopeptide regions of the α chains by the oxidative deamination function of the lysyl 
oxidase family. It includes lysyl oxidase (LOX) and lysyl oxidase-like (LOXL), LOXL2, 
LOXL3, and LOXL4 (19). LOX and LOXL has been shown to be active for fibrillar collagen 
while LOXL2 has been associated with basement membrane type IV collagen. As for the 
other isoforms, their substrate specificity have not been clearly defined (reviewed in (3)). It 
was reported that LOX is highly functional for growing, native collagen fibrils and was 
suggested that the intermolecular interaction between collagen molecules was important for 
the enzyme activity (20). Studies have shown that the binding sites for LOX in type I  
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collagen are in the triple helical region (21), potentially in the area with highly conserved 
sequences (Hyl-Gly-His-Arg) where it can catalyze the formation of aldehydes in the 
telopeptides of the adjacent collagen molecule (reviewed in (22)). The oxidative deamination 
activity of LOX enzymes can be inhibited by the well known lathyritic agent, β-
aminopropionitrile (BAPN)(23). The resulting Lys aldehydes (Lys
ald
) or Hyl aldehydes 
(Hyl
ald
) are determinants for the tissue-specific cross-linking pathway by their involvement in 
a series of spontaneous intra- or intermolecular reactions and thus provides the matrices with 
tensile strength and elasticity which are essential for the functional integrity of the tissue.  
 
 
 
Figure 1.2) Collagen cross-linking pathways LH: Lysyl hydroxylase, LOX: Lysyl oxidase, ACP: 
Aldol condensation product, Lys
ald
: Lys aldehyde, Hyl
ald
: Hyl aldehyde, Bivalent cross-links are 
shown in their reduced forms: HLNL:hydroxylysinonorleucine, DHLNL:dihydroxylysinonorleucine, 
HHMD: histidinohydroxymerodesmosine, HHL: histidinohydroxylysinonorleucine, Pyr: pyridinoline, 
Prl: pyrrole, d-Pyr: deoxypyridinoline, GG-: glucosylgalactosyl-, G-: galactosyl-, L-: lysyl-, H-: 
hydroxylysyl- 
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1.4.1 Immature bivalent reducible cross-links 
In fibrillar collagens, the telopeptides each contain one site of cross-link i.e. residue 9 
of the N-terminus (α1-9N, α2-9N) and residue 16 of the C-terminus (α1-16C). In the helical 
region, the cross-linking sites are found at residues 87 and 930. The Lys
ald
 and Hyl
ald
 at those 
telopeptidyl sites then spontaneously react with the helical Lys or Hyl residues and form two 
unique, tissue-specific, cross-linking pathways (Figure 1.2)(reviewed in (6,24)). 
Hydroxylysine aldehyde-derived pathway (Keto-amines). The cross-links derived 
from this pathway are mostly found in mineralized tissues such as bone and dentin. The Lys 
residues in the telopeptides are mainly hydroxylated, converted into Hyl
ald
 and react with the 
ε-amino group of Hyl or Lys residues in the helical region of the adjacent collagen molecule. 
The Schiff bases formed (dehydro-dihydroxylysinonorleucine (deH-DHLNL) and dehydro-
hydroxylysinonorleucine (deh-HLNL)) then undergo Amadori rearrangements to form 
hydroxylysino-keto-norleucine (HLKNL, Hyl
ald
 X Hyl) or lysine-keto-norleucine (LKNL, 
Hyl
ald
 X Lys) respectively. These keto-amine forms are more stable and may contribute, in 
part, to the insolubility of mineralized tissue collagen. However, for these immature cross-
links to withstand the acid hydrolysis, they have to be stabilized by the reduction process 
with tritiated sodium borohydride (NaB
3
H4), and analyzed in their reduced forms i.e. 
dihydroxylysinonorleucine (DHLNL) and hydroxylysinonorleucine (HLNL) (reviewed in 
(6,24)) . 
Lysine aldehyde-derived pathway (Aldimines). This leads to the formation of cross-
links in non-mineralized tissue such as skin and tendon. The Lys
ald
 in the telopeptides reacts 
with Hyl or Lys in the helical region of the juxtaposed molecule, forming dehydro-
hydroxylysinonorleucine (deH-HLNL, Lys
ald
 X Hyl) or dehydro-lysinonorleucine (deH-LNL, 
8 
 
Lys
ald
 X Lys). In addition, a unique reducible tetravalent cross-link, dehydro-histidino-
hydroxymerodesmosine (deH-HHMD) can be formed between the aldol condensation 
product of two Lys
ald
, histidine (His) and a helical Hyl (Lys
ald
 X Lys
ald
 X His X Hyl). Similar 
to the keto-amine cross-links, the aldimines are also analyzed in their reduced forms i.e. 
hydroxylysinonorleucine (HLNL), lysinonorleucine (LNL) and histidino-
hydroxymerodesmosine (HHMD). It is notable that the Hyl
ald
 and Lys
ald
 derived HLNL are 
structural isomers, therefore they both co-elute and are indistinguishable by the analysis 
methods commonly utilized (reviewed in (6,24)). 
 
1.4.2 Mature trivalent cross-links 
 In aging collagen, the levels of immature reducible cross-links were found to decline 
over time along with solubility of collagen while the strength of the tissue were shown to 
increase (25-27). These findings had led to the speculation of the presence of the 
maturational product of the immature cross-links. To date, in mineralized tissues, two major 
forms of the trivalent cross-links have been identified and characterized. In bone, unlike 
other tissues, it was shown that the level of immature cross-links remain relatively high, 
throughout life (28). The possible reasons could be, in part, that bone is under constant 
remodeling therefore new collagen is always formed. In addition, it is suggested that the 
mineralization process may inhibit the maturation of bivalent into trivalent cross-links (29) 
Pyridinium cross-links (Pyridinolines). These acid stable, ultraviolet sensitive 
fluorescent cross-links are predominant in collagen of mineralized tissues (e.g. bone, 
cartilage) in which Lys residues in the telopeptides are highly hydroxylated. Two major 
forms have been identified which include pyridinoline (Pyr, or known as hydroxylysyl 
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pyridinoline (HP)), and deoxy-pyridinoline (d-Pyr, or known as lysyl pyridinoline (LP)). It 
was pointed out that the term deoxy-pyridinoline may be misleading, since the formation 
occurs with the Lys rather than Hyl and may not involve the loss of water in the condensation 
reaction, as the name suggested (24). Pyridinoline, first identified by Fujimoto et al in bovine 
Achilles tendon, was shown to link between two Hyl
ald
 and one Hyl (Hyl
ald
 X Hyl
ald
 X Hyl) 
(30). Deoxy-pyridinoline ties between two Hyl
ald
 and one Lys (Hyl
ald
 X Hyl
ald
 X Lys) and 
was thought to originate from the reaction of LKNL with Hyl
ald
 (31). It is found mostly in 
mineralized tissues such as bone and dentin (32), and suggestive of having some role in the 
mineralization process (33). 
Several mechanisms have been proposed for the formation of Pyr (Hyl
ald
 X Hyl
ald
 X 
Hyl). Eyre and Oguchi suggested that it links three collagen molecules and forms from the 
condensation reaction between two keto-amines, 2 X HLKNL (Hyl
ald
 X Hyl) with the release 
of one Hyl residue(34). Alternatively, a condensation between one keto-amine and one free 
Hyl
ald
 from the same collagen molecule has been proposed (35) which is suggestive that it 
ties only between two collagen molecules. Another possible pathway is proposed through the 
condensation reaction between deH-DHLNL and its ketoamine form, HLKNL (36) 
Pyrroles. This unstable compound, which reacted to p-dimethylaminobenzaldehyde 
and called Ehrlich chromogen, was identified by Kuyper et al from bovine tendon collagen 
(37) and later isolated from bovine bone collagen (38). This trivalent cross-link was found 
exclusively at the N-telopeptide region and cross-linked between Hyl
ald
 X Lys
ald
 X Lys or 
Hyl (37-39). The presence and abundance of pyrrole cross-links have been correlated to the 
strength of tissues since decreased levels are found with increasing age and in osteoporotic 
bone (reviewed in (39)). 
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1.5 Type I collagen-based mineralization 
The mineralized tissues (e.g. bone, dentin, enamel and cementum), are formed from a 
complex series of events regulating the interaction between the two major factors i.e. the 
inorganic mineral phase and the organic matrix. From the dry weight of the mineralized 
tissue, the mineral phase constitutes about two-thirds of the mass while the other one-third is 
the organic phase, of which 85-90% is collagen; 10-15% is cells and non-collagenous 
proteins. The mineral phase provides stiffness while the collagen fibers provide the ductility 
and ability to absorb energy to bone tissue. Unlike other mineralized tissues, the major 
organic component in enamel is not collagen but amelogenin and enamelin (40). Type I 
collagen matrix serves as a structural framework to support the nucleation and growth of 
mineralized nodules. In specific tissue or areas where mineralization occurs, the highly 
saturated level of the mineral ions (e.g. calcium and phosphate ions) has to be maintained by 
specific regulatory mechanisms. Mineral deposition occurs both within and between the 
fibrils, initially forming intermediate precursors (e.g. amorphous calcium phosphate (ACP), 
or, dicalcium phosphate dihydrate (DCPD)) and gradually mature into the stable form, 
hydroxyapatite ((Ca10(PO4)6(OH)2)/HAP) (41). Several studies have tried to elucidate the 
regulatory mechanisms of the initiation and progression of collagen-based mineralization, 
however, the data obtained from those studies cannot give enough clarifications. By using the 
calcifying avian tendon, a model for mineral formation in vertebrate calcifying tissues, and 
an atomic force microscopy (AFM), Siperko and Landis in 2001, have shown that collagen-
based mineralization is an ordered and tightly regulated process. As depicted in Figure 1.3, 
after the spontaneous assembly of collagen molecules, mineral deposition induces the 
formation of crystal platelets in the gaps of the hole and overlap zones, which continuously  
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grow in size through the gap and along the axis of the fibrils in all dimensions to the level of 
collagen fiber (a-d). Association of collagen fibers, with the ongoing process of mineral 
 
Figure 1.3) Schematic diagram of the putative organization and interaction of collagen and 
mineral at different structural levels of hierarchy for a calciﬁed vertebrate tissue. (a) Based on 
the model of collagen assembly proposed by Hodge and Petruska (1963) and the manner of its 
association with mineral described by Weiner and Traub (1986), McEwen et al.  (1992), and Landis et 
al.  (1993, 1996a), crystal platelets nucleate in collagen channels or gaps created by periodic (67 nm) 
hole and overlap zones. (b) Crystal platelets grow in length  along  their  crystallographic  c-axes  and  
in  width  through  the  channel  or  gap  spaces  (Landis  et  al., 1993).  (c)  As collagen 
macromolecules grow as well to microﬁbrils and ﬁbrils (20 nm in diameter), crystals fuse into larger 
and thicker plates in which their periodic deposition (50–70 nm) and parallel nature are still 
maintained (Landis et al., 1996a). At this stage, interﬁbrillar plates may be developing. (d) The crystal 
plates grow larger in all dimensions at the level of collagen ﬁbers (80 nm and greater in diameter). (e) 
Fibers next associate to create a series of parallel plate aggregates that may vary in length,  width,  
and  thickness.  Some  of  the  aggregates  may  represent  the  interﬁbrillar  plates  formed  earlier.  A 
frequent thickness observed for the aggregates is 80 nm and a frequent size along their length is 500 
nm. Individual plate aggregates are initially separated by 50 nm (e), but this space gradually 
disappears as mineral deposition proceeds in the tissue and aggregates would grow to thicknesses of 
130 nm (f). Edges of plate aggregates still maintain 50- to 70-nm periodicity, indicative of the basic 
collagen structure underlying mineral formation. (g) Ultimately the plate aggregates become lamellar 
in shape and constitute a portion of bone or mineralized tendon. Independent of the mineralization 
associated with the hole and overlap zones, there is surface mineralization (Nylen et al., 1960; Landis 
et al., 1996b) of the collagen structures in b–f. This aspect of mineral formation is not depicted in b–
d. (e) In the schematic (e) is equivalent to Fig. 3b on 90° rotation. Reprinted from J Stuct Biol, 2001, 
Vol 135 ( 3), Siperko  L.M. & Landis W.J. Aspects of mineral structure in normally calcifying avian 
tendon, p.313-20, Copyright (2001), with permission from Elsevier. 
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deposition, generates parallel plate aggregates that finally represent the lamellar pattern in 
bone or mineralized tissue (e-g) (42). Lees in 2003 had proposed that mineralization of 
collagen rely largely on the molecular packing and chemical structure of collagen molecules. 
The author has shown that the deposited minerals replace the same amount of water removed 
from the collagen fibrils (43).  
For this reason, a proper formation of the collagenous template is indeed crucial for 
the mineralization process and alteration in the collagen fibril formation by any factors (e.g. 
intrinsic or extrinsic factors) may affect the mineral deposition. Defective collagen matrix 
from structural alteration of the collagen molecules results in abnormal mineralization 
(18,44), as shown in the studies of osteogenesis imperfecta (OI) (45-46), osteoporosis (47).  
It has also been observed in several studies performed in our lab that, smaller collagen fibrils 
formed by mouse osteoblastic cell line, MC3T3-E1, overexpressing decorin (DCN) or lysyl 
hydroxylase 2b (LH2b) are not efficient templates for mineral deposition (48-49). LH2b is 
known for hydroxylating the lysine (Lys) residues in the telopeptide regions of collagen 
while DCN, a member of the SLRPs family, is a negative regulator of collagen 
fibrillogenesis and mineralization (48,50-51).  
 
1.6 Hydroxylysine glycosylation in collagen 
 This type of post-translational modification is specific to collagens and proteins with 
collagen-like triplet repeats, Gly-X-Y, and resulting in two forms of glycosylated Hyl which 
are galactosylhydroxylysine (G-Hyl) and glucosylgalactosylhydroxylysine (GG-Hyl). The 
formation involves three sequential enzyme-mediated steps of Lys hydroxylation, Hyl 
galactosylation and finally, G-Hyl glucosylation, as shown in figure 1.4. 
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1.6.1 Lysine hydroxylation 
Enzymes and reactions. Lysyl hydroxylase (LH) (EC 1.14.11.4) is one of the 2-
oxoglutarate dioxygenases which catalyzes the hydroxylation reaction of Lys residues in the 
procollagen α chains and proteins with collagenous sequences, co- and post-translationally. 
The reaction requires ferrous iron, oxygen, 2-oxoglutarate and ascorbate as cofactors and in 
turn releases succinate and carbon dioxide (CO2) along with the formation of Hyl (Figure 
1.4A) (52). In collagens, Hyl residues are present exclusively in the Y position of X-Y-Gly 
 
Figure 1.4) Enzymatic reactions catalyzing Lys hydroxylation and subsequent glycosylation. 
Reaction catalyzed by (A) lysyl hydroxylase (LH), (B) collagen galactosyltransferase (GT), and (C) 
collagen glucosyltransferase (GGT). Reprinted from J Cell Physiol, 212(2), Myllyla et al, Expanding 
the lysyl hydroxylase toolbox: New insights into the localization and activities of lysyl hydroxylase 3 
(LH3), p.323-9, Copyright (2007), with permission from John Wiley & Sons, Inc. 
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triplets while in the non-helical region of α chains, Gly is replaced by serine in the N-
telopeptide (X-Hyl-Ser) and by alanine in the C-telopeptide (X-Hyl-Ala) of the α chains.  
These findings were suggestive of the presence of different LH isoforms, which were later 
identified and characterized. Some of the Hyl residues, exclusively in the helical region, 
serve as attachment sites for carbohydrate units, galactose (G-) or glucose-galactose (GG-) 
forming G-Hyl and GG-Hyl respectively. All of the Hyl species were shown to participate in 
the formation of intermolecular cross-links. The level of Lys hydroxylation varies among 
different collagen types, same collagen types in different tissues, developmental stages and 
pathological conditions (reviewed in (3,6,52).  
 
Lysyl hydroxylase isoforms. The differences in the sequence-specific sites of Lys 
hydroxylation and the varied levels of Hyl found in different tissues and collagen types had 
prompted the search for the other LH isoforms and to date 3 of them were identified, LH1, 
LH2 and LH3 encoded by procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase (PLOD; 
PLOD1, PLOD2 and PLOD3 respectively). Unlike the other two isoforms, the gene encoding 
LH2 is alternatively spliced leading to two different variants designated as LH2a and LH2b 
(or the short and long form, respectively) (53). LH2b contains 63 bp of an extra exon named 
13A (53), from which the amino acid sequence were shown to be conserved between human, 
mouse and rat (54).  Among the two variants, LH2b was shown to be the major isoform in 
most of the tissues (53), including bone (55). The three LH isoforms were cloned and 
characterized in human (56-57), mouse (58) , rat (54) and zebrafish (59-60) whereas one 
orthologue is found in C. elegans (61).  From phylogenetic analysis, among the three 
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isoforms, LH3 is the oldest isoform showing the most homology to the ancestral LH gene in 
C. elegans, while LH1 and LH2 are derived from more recent gene duplications (58). 
 
Substrate specificity of lysyl hydroxylase isoforms. Several studies have tried to 
determine the sequence or collagen type specificity for the activities of the three LH isoforms 
by means of different substrate types (62-63), correlation of the mRNA levels with collagens 
(64), measuring the levels of end products (55,65), evaluating the different responses to LHs 
inhibitor (66), collagen analysis from patients with known disorders related to LHs (67), or 
LHs deficient mice (68-70). Collectively, however, it was shown that there are no strict 
collagen types or sequence requirements for each LH isoforms. It was suggested that LH2b 
mainly hydroxylates Lys residues in the telopeptide regions (54-55,62,71-72) while LH1 
preferentially catalyzes the hydroxylation of Lys residues in the triple helical region of 
fibrillar collagen, especially the residues involved in the intermolecular cross-links (62,65-
66,69,73). As for LH3, its contribution in hydroxylating the Lys residues in the helical region 
of fibrillar collagen is still unclear, but it showed its critical roles for type IV and type VI 
collagen biosynthesis (62,69-70). In the condition that the function of one isoform was 
impaired, compensatory mechanism from the other 2 isoforms were speculated, and may 
depend in most part on the tissue-specific expression of each isoform (68).  
 
Subcellular localization of lysyl hydroxylase isoforms. Lysyl hydroxylase 1 has been 
localized to the endoplasmic reticulum (ER) with a unique mechanism from the 40 amino 
acid stretch at the C-terminus of the LH1 sequence, unlike the other proteins containing the 
known ER-retention motifs, KDEL or double lysine. This unique sequence is present with 
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high degree of homology in all the three LH isoforms indicating that all the isoforms employ 
the same ER-retention mechanism (74-75).   
Unexpectedly, LH3 can be localized both inside and outside of the cell, since it can 
be detected in the cell lysate, at the cell surface and in the cultured medium. The extracellular 
LH3 is of higher molecular size than the intracellular LH3 from the asparagine-linked (N-
linked) glycosylation during the secretion process. The potential roles of the secreted LH3 
have been shown by the ability of recombinant LH3 to modify extracellular proteins (e.g. 
serum proteins, secreted proteins or proteins on the cell surface) in their native state, 
suggesting a possible catalytic activity for native collagen (76) which contradicts the earlier 
reports that triple helical conformation inhibits further modifications (77-78). However, the 
specific substrates (e.g. collagens or proteins with collagenous sequences) for the 
extracellular function of LH3 have never been reported.  
Moreover, to date, LH3 is the only enzyme modulating the transfer of glucose units to 
G-Hyl residue, while there are some conflicting data regarding the galactosylation activity of 
LH3 in transferring galactose units to free Hyl (70,79-81). The glycosyltransferase activity of 
LH3 will be reviewed in more detail in section 1.6.2. 
 
Lysyl hydroxylase isoforms and human disorders. Mutations in PLOD1, which led to 
a deficiency in the LH1 enzyme, were shown to be the cause of Ehlers-Danlos syndrome 
EDS type VIA, a disorder characterized by neonatal muscle hypotonia, progressive 
kyphoscoliosis, abnormal scarring and easy bruising of the skin, increased risk of arterial 
rupture and ocular fragility (82-87). From these patients, there was a significant decrease in 
the level of Hyl in the skin collagen and the cross-linking pattern was also altered (73,88-89). 
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In addition, mutations in PLOD1 were also found in patients affected with Nevo syndrome, a 
rare, autosomal recessive disorder with clinical features similar to those of EDS VIA (90). 
Plod1 null mice, recently generated, showed muscular hypotonia, increased risk of aortic 
rupture, and alteration in collagen fibrils. A decrease in Lys hydroxylation and a change in 
the cross-linking pattern were found to be varied among different tissues of the knockout 
mice, showing the most significant changes in the skin rather than the other tissues, similar to 
the phenotypes seen in EDS VIA patients (68). Interestingly, in another subtype of EDS type 
VIB, PLOD1 was not mutated and LH activity and cross-linking profiles were normal, 
however decreases in the mRNA expression of LH2 and LH3 have been observed (91-92). It 
has been reported, most recently that mutations in the CHST14, encoding dermatan-4-
sulfotransferase 1 (D4ST-1) involved in the biosynthesis of the dermatan sulfate 
glycosaminoglycan (GAG) chains, may be one cause of EDS type VIB (93-94). In addition, 
another novel form of EDS showing similar clinical features with the kyphoscoliotic form 
was designated as spondylocheiro dysplastic form of EDS (SCD-EDS). Interestingly, in this 
form of EDS, Lys and Pro residues in the patients’ collagen were underhydroxylated despite 
the normal LH and P4H activities measured from the cell homogenates. It was reported that 
the disorder has been attributed to a mutation in the Zn
2+
 transporter gene, SLC39A13. The 
mutation most likely resulted in the build up of Zn
2+
 in the ER, which competitively inhibited 
the function of Fe
2+
, the essential cofactor for LH and P4H activities (95).  
Mutation in PLOD2, resulting in underhydroxylation of Lys residues in the 
telopeptide region of collagen, have been identified in patients with Bruck syndrome type 2, 
an autosomal recessive inherited disorder, characterized by fragile bones, congenital joint 
contractures, scoliosis and osteoporosis (72,96-97). However, Bruck syndrome type 1 was 
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identified in one family showing the link to chromosome 17p12, while no mutation was 
found in PLOD2, suggesting heterogeneity of the syndrome (67). Most recently, Kelley et al 
have shown that mutations in FKPB10 (also known as FKPB65), encoding a chaperone 
protein the FK506 binding protein 10, located in chromosome 17p12, are the causes of Bruck 
syndrome type 1 (98). To date, the generation of Plod2 manipulated mice model, has not 
been reported.  
The biological significance of PLOD3 has been illustrated from the LH3-knockout 
mice which were embryonically lethal at E9.5 from abnormal type IV and type VI collagen 
biosynthesis and distribution which resulted in the fragmentation of the basement membrane 
(69-70,99). Recently, mutations in PLOD3 have been associated with human disorders 
affecting several connective tissues (100-101). (detailed description in section 1.6.2) 
 
1.6.2 Hydroxylysine glycosylation  
Enzymes and reactions. Glycosylated hydroxylysines are generated by the group of 
enzymes known as collagen glycosyltransferases, which transfer the carbohydrate units (D-
galactose and D-glucose) O-glycosidically to the hydroxyl group of specific Hyl residues in 
the α chains. They consist of hydroxylysyl galactosyltransferase (GT) (EC 2.4.1.50) and 
galactosylhydroxylysyl glucosyltransferase (GGT) (EC 2.4.1.66) which form 
galactosylhydroxylysine (G-Hyl) and glucosylgalactosylhydroxylysine (GG-Hyl) 
respectively. Structural analysis of GG-Hyl, by Spiro in 1967, showed that galactose is 
attached to the hydroxyl group of Hyl by a β-glycosidic bond, while glucose is linked by an 
α-glycosidic bond to C-2 of the galactose unit forming the complex structure of 2-O-α-D-
glucopyranosyl-O-β-D-galactopyranosylhydroxylysine (Figure 1.5) (102). Both reactions  
19 
 
 
require the presence of free ε-amino group of the Hyl residue, the UDP-galactose or UDP-
glucose as carbohydrate donors, and the most preferred bivalent cation cofactor, Mn
2+
 (103). 
The complete triple helix structure of collagen molecule inhibits further glycosylation (77-
78).  These enzymes have been extensively studied and characterized from tissue extracts of 
different species (104-107), while the highest activities were obtained from whole chick 
embryo extract. About a decade ago, these enzymatic activities were found in the 
multifunctional enzyme, LH3 (79-80,108). 
 
The role of LH3 as collagen glycosyltransferase. Lysyl hydroxylase 3 and C. elegans 
LH, the only ortholog in nematode, were both shown to be multifunctional enzymes 
containing the LH, GT and GGT activities in vitro (108). The GT and GGT activities of LH3 
were identified by the ability of the recombinant LH3 generated from SF9 cells and the 
product of cell-free translation of LH3 cDNA in transferring the sugar moieties to Hyl 
 
Figure 1.5) The structure of di-glycosylated hydroxylysine. The di-glycosylated hydroxylysine 
was characterized from glomerular basement membrane showing the structure of 2-O-α-D-
glucopyranosyl-O-β-D-galactopyranosylhydroxylysine. This research was originally published in 
Jounal of Biological Chemistry. Spiro R.G. The structure of the disaccharide unit of the renal 
glomerular basement membrane. J Biol Chem. 1967; 242: 4813-23. © The American Society for 
Biochemistry and Molecular Biology.  
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residues in calf skin gelatin substrate (79-80). The GGT activity was also confirmed by the 
partial inhibition of the activity from the binding of the polyclonal antibody of LH3, as well 
as the antibody raised against chicken galactosyl glucosyltransferase enzyme (79). In LH3, 
the domain and specific sequences for the GT and GGT activity (aspartic acid (D) repeats or 
DXD-like motifs) are located in the N-terminus while those for the LH activity are in the C-
terminus. The LH and the glycosyltransferase enzymatic activities are shown to be 
independently regulated (108). The biological significance of the GGT activity of LH3 has 
been demonstrated from the studies of LH3 deficient mice which had an embryonic lethal 
phenotype at E9.5 due to the impaired type IV collagen biosynthesis and secretion resulting 
in fragmentation of the basement membrane. The severity of the phenotype showed a 
significant correlation to the level of GGT activity (69-70) which was further shown to be 
essential for the oligomerization and secretion of type VI collagen (99). As for the GT 
activity of LH3, when compared to the GGT, it has been shown to be significantly lower (79-
80) or undetectable (70,81). The biological significance was always in question until 
recently, a novel family of collagen galactosyltransferase enzyme encoded by the GLT25D1 
and GLT25D2 has been discovered and characterized in regards to the tissue distribution and 
enzymatic activity but the substrate specificity was not clearly defined (81).  
As mentioned in section 1.6.1, LH3 is also localized and functional outside the cells, 
since it can be detected in the culture medium, serum and at the cell surface (76). However, 
the specific substrates (e.g. collagens or proteins with collagenous sequences) for the 
extracellular LH3 are still not known. By overexpressing the glycosyltransferase-deficient 
fragment of LH3 or silencing the gene in HT1080 cell, exclusively producing type IV 
collagen, abnormal cell morphology, growth and eventually cell death were observed.  
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Interestingly, when the purified glycosyltransferase-deficient fragment was added to the 
HT1080 cells exogenously, similar effects on the morphology and vitality of the cells were 
seen faster. However, the effects on the cells were reversible upon removal of the mutated 
fragments. The effects in the other cell types studied (adult lung fibroblasts, adult skin 
fibroblasts and osteosarcoma cells), were very mild, if any, indicating cell-type specificity, 
probably in relation to the receptor protein composition on the cell membrane (109). 
Moreover, Risteli et al in 2009 reported that lowered level of LH3 resulted in decreased 
deposition, impaired organization of collagens, and cell morphology changes from the 
alteration in the organization of cytoskeletal proteins (101). 
 
Identification of novel collagen galactosyltransferases. Most recently, Schegg et al in 
2009 have cloned and characterized novel collagen galactosyltransferase enzymes, named 
glycosyltransferase 25 domain 1 and 2, encoded by the GLT25D1 and GLT25D2 
respectively, showing that they are capable of transferring galactose, but not glucose units, to 
collagens and mannose-binding lectin (MBL) (81), a collagen-like protein containing 
glycosylated hydroxylysines (110). In the same study, LH3 was shown to be the sole GGT 
enzyme while the GT activity was not detected. Among the two isoforms, GLT25D1 
exhibited broad expression in several fetal and adult human tissues, and was suggested to be 
the main collagen galactosyltransferase enzyme, while GLT25D2 was only detected in a few 
cell types (81). Unlike LH3, GLT25D1 and GLT25D2 were shown to be strictly maintained 
in the ER by the ER retention motif, RDEL (81,111). Immunofluorescence analysis in liver 
cells showed that GLT25D1 co-localizes with MBL and LH3 in the ER (111). 
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1.6.3 Glycosylated hydroxylysines in collagen fibrillogenesis 
To date, the biological roles of glycosylated Hyl residues have not been clearly 
defined, however it is evidently seen in collagens that, optimal levels of Hyl glycosylations 
are essential for the formation of normal extracellular matrices hence healthy connective 
tissues. With their unique characteristics of having bulky sugar units projecting outwards and 
orienting parallel to the backbone of the collagen molecules (9), they are believed to be one 
of the factors controlling collagen fibril diameter. Previous studies have shown that collagens 
with higher level of Hyl glycosylation formed fibrils with smaller diameter in vitro (8-
11,112), possibly from the extensive amount of sugar projections preventing the regular 
hexagonal packing of the collagen molecules. Besides, the hydrophilic nature of the sugar 
units may attract more water to the surface of the collagen molecules, possibly affecting the 
interactions between collagen molecules or between collagen and its binding proteins.  
 
1.6.4 Glycosylated hydroxylysines in collagen cross-linking 
Several studies, analyzing type I collagen from various tissues and species, had 
identified Hyl residue 87 in both α1 and α2 chains to be mainly di-glycosylated (113-117). In 
bone type I collagen, the immature bivalent cross-links derived from Hyl residue 87 and 
Hyl
ald
 in the C-terminal telopeptide were found to be mainly di-glycosylated (reviewed in 
Table 1.1) (118-120).  Interestingly, pyridinoline (Pyr), the trivalent cross-link maturing from 
the condensation reaction between two DHLNL complexes, predominantly found in human 
bone was found to be mono-glycosylated (G-Pyr) or non-glycosylated (38,121-122). 
Analysis of the posttranslational modifications from various functional sites in rat femur has 
shown an inverse correlation between the level of glycosylated Hyl residues and pyridinium  
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cross-links, especially GG-Hyl and Pyr (124). These observations may implicate a potential 
negative regulatory role of the glucose units in the GG-Hyl residue for the maturation of 
collagen cross-links, which occurs spontaneously between two juxtaposed bivalent cross-
links. The possible explanations would be, firstly, that the bulkiness of the galactose-glucose 
attachments may sterically hinder the reaction forming the trivalent cross-links. However, 
GG-Pyr has been detected in several other tissues (121) therefore, the steric hindrance caused 
by the glucose unit seems less likely. Secondly, since the presence of GG-Pyr shows high 
tissue specificity, differences in the micro-environment between tissues may have a selective 
role in the cross-links maturation process.  
Table 1.1 Review of glycosylated cross-links identification. (38,119-123)  
 
Abbreviations: HLNL:hydroxylysino-norleucine, DHLNL:dihydroxylysinonorleucine, HHMD: 
histidinohydroxymerodesmosine, Pyr: pyridinoline, GG-: glucosylgalactosyl-, G-: galactosyl-, Hyl: 
hydroxylysine, α1-16C: residue 16 at C-telopeptide of alpha 1 chain, α1-87: residue 87 at helical 
region of alpha1 chain, α2-87: residue 87 at helical region of alpha 2 chain.  
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1.6.5 Glycosylated hydroxylysines in extracellular matrix formation 
Spiro in 1969 reported higher level of GG-Hyl residues in insoluble collagen 
compared to the soluble one purified from the same tissue (e.g. rat skin or rat tail tendon), 
suggesting the possibilities that glucosylation may continue after cross-links have been 
formed or that the collagen molecules with more GG-Hyl residues would be deposited and 
retained in the matrix (125). Later, it was shown that the transfer of the glucose units to G-
Hyl by the glucosyltransferase enzyme only occur before the complete folding of the α 
chains into triple helical conformation (77), therefore the continued glucosylation of collagen 
molecules would be less likely. Moreover, it has been reported that collagens with higher 
levels of glycosylation were shown to have increased resistance to mammalian collagenase 
digestion (9). In skin fibroblast culture from the patients with dominant epidermolysis 
bullosa simplex (DEBS), a disorder with defective GGT activity from decreased level of LH3 
protein, collagen deposition into the extracellular matrix was reported to be lower when 
compared to the control (101).  Collectively, the data from these previous reports suggested 
that collagen molecules with higher levels of glycosylation may be deposited into the matrix 
and stabilized by the formation of cross-links while collagen with lower levels of 
glycosylation may be less cross-linked and more susceptible to collagenase digestion.  
 
1.6.6 Glycosylated hydroxylysines as markers of collagen metabolism 
In the process of collagen metabolism, these glycosylated Hyl residues are not re-
utilized by the cell for collagen biosynthesis; therefore, they are secreted into the serum and 
subsequently excreted with urine (126). Comparing to Hyp, the levels of Hyl-glycosides 
excreted in urine were not affected by normal diets and shown to quantitatively reflect the 
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degree of collagen turnover and somehow indicative of the tissue origin. Higher urinary 
excretion of total glycosylated Hyl has been shown in healthy children and some heritable 
connective tissue disorders with higher degree of collagen turnover. Among different 
connective tissue collagens, G-Hyl is the predominant form in bone type I collagen resulting 
in the uniquely low GG-Hyl to G-Hyl ratio, which was also observed when measured in 
urine.  Therefore, these glycosylated Hyl residues and their ratios were used as biological 
markers for collagen turnover (127), especially in bone, a marker of growth in children (128), 
and as a tool to monitor treatment response in patients (129-132). The level of free G-Hyl in 
serum was also shown to be a useful marker for bone resorption (133). In addition to the 
direct measurement of the level of glycosylated Hyl residues, the GGT activity in serum has 
been indicated as a sensitive marker for collagen metabolism in various rheumatic diseases 
(134) neuromuscular, hepatic and dermatological diseases (135-137), and  after physical 
exercise (138-139). 
 
1.6.7 Glycosylated hydroxylysines and age-related variations 
Age-related variation in glycosylation has been observed from the analysis of human 
and rat skin collagen which demonstrated a rapid decrease of the GG-Hyl/free Hyl ratio and a 
somewhat constant G-Hyl/free Hyl ratio during maturation, therefore suggesting a functional 
role for GG-Hyl while G-Hyl serves as an intermediate (140). Cetta et al in 1982 analyzed 
rabbit Achilles tendon of different ages and showed fast decreases in the level of GG-Hyl and 
GG-Hyl/G-Hyl ratio during fetal life and in the first month after birth, which corresponds to 
the rapid increase in the collagen fiber diameter. The markedly decrease level of GG-Hyl, as 
compared to G-Hyl, points to the possibility of a conversion of GG-Hyl into G-Hyl (141). A 
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glucohydrolase enzyme, with specific activity for GG-Hyl residues has been purified from 
chick embryo (142), rat spleen (143), and detected in cell lysate of human skin fibroblast 
(144). However, characterization of the GG-Hyl α-D glucosidase enzyme from rat kidney has 
demonstrated that the enzyme has optimal activity on free GG-Hyl and to a lesser degree on 
GG-Hyl containing peptides and proteins respectively. This could suggest the potential role 
of the enzyme at the later stage of the collagen metabolism process rather than at the collagen 
molecules in the extracellular matrix (145).  
 
1.6.8 Glycosylated hydroxylysines and protein interactions 
Several studies had identified, in type I collagen from different species, the 
glycosylation sites (reviewed in Table 1.2) which are noticeably present more to the N-
terminal region of the collagen molecule and are located in close proximity to or in the gap 
zone, according to the functional and ligand binding regions mapped in one D-period repeat 
containing the complete collagen sequence from elements of 5 monomers and include an 
overlap and gap zone (146). The gap zone was shown to be the site for the initiation and 
progression of mineralization (Figure 1.2) (42). The presence of the glycosylated Hyl 
residues exclusively to this region, may suggest a regulatory role of the sugar attachments for 
the mineralization process either directly by facilitating the deposition of minerals or 
indirectly by interacting with other non-collagenous proteins, both of which have never been 
investigated.  
Moreover, those mapped regions were shown to be the binding sites of various 
extracellular proteins e.g. integrins, proteoglycans, phosphophoryn and discoidin domain 
receptor 2 (DDR2) (146). The functional association between these proteins and Hyl  
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glycosylation has never been elucidated except for DDR2, a tyrosine kinase receptor specific 
for collagen, which its activation was reported to be significantly reduced after 
deglycosylation of the collagen by sodium-m-periodate (148). Moreover, it was demonstrated 
that the degree of collagen glycosylation affects the arthritogenicity to type II collagen. The 
incidence and severity of the arthritis showed strong correlation to the level of G-Hyl 
residues (149). 
 
Table 1.2 Review of the glycosylated hydroxylysine sites identification. 
                    (103,113-116,147)  
 
                             *: type not specified, CB: cyanogens bromide peptide, G: glycine, M: 
methionine, K: lysine, H: histidine, R: arginine, I: isoleucine, P: proline, E: 
glutamic acid, L: leucine, F: phenylalanine, A: alanine G-Hyl: 
galactosylhydroxylysine, GG-Hyl: glucosylgalactosylhydroxylysine,  
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1.7 Collagen glycosylation-related human disorders 
1.7.1 Levels of collagen glycosylation 
The levels of collagen glycosylation have been shown to vary among different 
collagen types (5,150), different functional regions in the same tissue (124,151), different 
tissues, developmental stages (103,152-153) and diseased conditions (100-101,154-160).  
Among different collagens, the abundance of free Hyl and glycosylated Hyl residues in the 
tissue varies with the distinct expression and the organization degree of collagen types. The 
highest content has been reported in the less organized collagen type IV-rich basement 
membrane, in a disaccharide form (GG-Hyl). Lower levels of Hyl glycosides are found in 
collagen types that form organized fibrils such as type I, II and III (150), among which, type I 
collagen has the lowest level of glycosylation.  The abundance of the two forms of modified 
Hyl residues (GG-Hyl, G-Hyl and their ratio) also shows varying levels in the same collagen 
type from different tissues e.g. bone, skin and tendon (127,161). Besides, species specific 
difference in the GG-Hyl to G-Hyl ratio has been observed between bone type I collagen 
from human and rat (162). The degree of Hyl glycosylation has been shown to have a 
significant contribution towards the quality of extracellular matrices synthesis, organization 
and maturation, as seen from several connective tissue disorders in which different levels of 
collagen glycosylations were observed. 
 
1.7.2 Human disorders with collagen underglycosylation 
 Underglycosylation of collagen, as a result of the deficiency in the GGT enzymatic 
activity in the skin and serum, was detected in a group of patients from one family with 
dominant epidermolysis bullosa simplex (DEBS), characterized by the occurrence of serous, 
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nonscarring blistering of the skin after minor trauma (154).  Most recently, the cause for the 
defective GGT activity in this specific subtype of DEBS has been reported, showing four 
polymorphic nucleotides in the promoter and 5’ untranslated region of the PLOD3 gene but 
no mutation in the coding region, resulting in about 67% LH3 mRNA expression (101). In 
another recent finding, two heterozygous mutations in the PLOD3 coding region, which 
resulted in a significant decrease in GGT activity, have been associated with a rare syndrome 
of congenital malformations affecting several tissues and organs and shared common features 
with several other known collagen disorders (100).  Biochemical analysis of collagens from 
mice models for Kashin-Beck disease, a rare degenerative, osteoarticular disorder associated 
with severe skeletal deformation and dwarfism, showed elevated Lys hydroxylation in bone 
type I collagen, and to a lesser degree in type II collagen which also showed a slight increase 
in the level of glycosylated Hyl residues (163). Interestingly, significant decrease in the 
levels of GG-Hyl but not G-Hyl residues were reported in bone type I collagen of mice 
receiving long term supplementation of fulvic acid, shown to be one of the main causes for 
Kashin-Beck disease, (164).   
 
1.7.3 Human disorders with collagen overglycosylation 
Overglycosylation of bone type I collagen, on the other hand, has been associated 
with poor bone quality as seen in some osteogenic disorders i.e. osteogenesis imperfecta (OI) 
(156,160), post-menopausal osteoporosis (155,158,165-166) osteosarcoma, and osteofibrous 
dysplasia (159). In addition, higher level of glycosylated Hyl and GG-Hyl to G-Hyl ratio 
were observed in the granulation tissue while lower levels were found in normal skin and 
scar tissue respectively, suggesting the role of Hyl glycosylation in the wound healing 
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process (167). Brinckmann et al in 1999 has shown an increased level of Hyl glycosylation as 
a result of overhydroxylation of skin type I collagen from the patients suffering chronic 
venous insufficiency which resulted in lipodermatosclerosis, a condition characterized by 
excessive accumulation of extracellular matrices and leading to hardening of the skin (157). 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 2 
 
Specific Aims 
 
 In type I collagen, the presence of glycosylated hydroxylysines, i.e. 
galactosylhydroxylysine (G-Hyl) and glucosylgalactosyl hydroxylysine (GG-Hyl) are long 
known, and their level alteration has been associated with several human connective tissue 
disorders. However, the enzymatic mechanism for the formation of G-Hyl and GG-Hyl in 
type I collagen has not been clearly defined. Moreover, the biological roles of these Hyl 
species in type I collagen still remained elusive. Lysyl hydroxylase 3 (LH3), the 
multifunctional enzyme containing both Lys hydroxylation and Hyl glycosylation activities, 
is designated as the major collagen glucosyltransferase enzyme with some conflicting data 
with its collagen galactosylation activity. From the previous publications on LH3, data 
regarding its role for type I collagen has been very limited. Preliminary studies from our 
laboratory have shown that LH3 is expressed in mouse osteoblast cell line, MC3T3-E1 (MC), 
mainly producing type I collagen. Therefore, the studies to be shown here in this dissertation 
were aimed to uncover the role of LH3 for type I collagen by utilizing MC3T3-E1 cell line as 
a model. The specific aims were as follow: 
1. To elucidate the enzymatic function of LH3 for bone type I collagen by generating 
MC cell-derived clones stably suppressing LH3 gene (Sh clones) with short hairpin 
RNA technology. 
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2. To investigate the effect of LH3 suppression on the level of Lys hydroxylation and 
Hyl glycosylations in type I collagen, collagen fibrillogenesis, collagen cross-linking, 
collagen matrix formation and mineralization. 
3. To identify specific molecular loci and types of Hyl glycosylation in MC and Sh 
collagen with mass spectrometry. 
During the course of this study, novel collagen galactosyltransferase enzymes, 
glycosyltransferase 25 domain 1 and 2 (GLT25D1 and D2) were identified and characterized. 
Among the two isoforms, we have determined that only Glt25d1 is expressed in MC cells 
(Chapter 3: Study I). Therefore, an additional aim was: 
4. To elucidate the function of Glt25d1 for bone type I collagen by generating MC cell-
derived clones stably suppressing Glt25d1 (G_Sh clones) with short hairpin RNA 
technology and characterize their collagens. 
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Abstract 
Lysyl hydroxylase 3 (LH3), encoded by Plod3, is the multifunctional collagen 
modifying enzyme possessing the lysyl hydroxylase (LH), hydroxylysyl 
galactosyltransferase (GT) and galactosylhydroxylysyl glucosyltransferase (GGT) activities. 
Though an alteration in type I collagen glycosylation has been implicated in several 
osteogenic disorders, the role of LH3 in bone physiology has never been investigated. In 
order to elucidate the function of LH3 in bone type I collagen modifications, we have 
employed a short hairpin RNA technology in mouse osteoblastic cell line, MC3T3-E1 (MC), 
generated single cell-derived clones stably suppressing LH3 (Sh clones) and characterized 
the phenotype. Plod3 expression and the LH3 protein levels in the Sh clones were 
significantly suppressed when compared to the controls, MC and the clone transfected with 
an empty vector (EV). In comparison to controls, type I collagen synthesized by Sh clones 
(Sh collagen) showed a significant decrease in the extent of glucosylgalactosylhydroxylysine 
with a concomitant increase of galactosylhydroxylysine while the total number of 
hydroxylysine residues was essentially unchanged. In an in vitro fibrillogenesis assay, Sh 
collagen showed accelerated fibrillogenesis compared to the controls. In addition, when 
recombinant LH3-V5/His protein was generated in 293 cells and subjected to GGT/GT 
activity assay, it showed GGT but not GT activity against denatured type I collagen. The 
results from this study clearly indicate that the major function of LH3 in osteoblasts is to 
glucosylate galactosylhydroxylysine residues in type I collagen and that lowering of LH3 
level significantly affects type I collagen fibrillogenesis.  
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Introduction 
Collagens are a large family of extracellular matrix proteins comprising at least 29 
different genetic types (1-2). Among those types, fibrillar type I collagen is the most 
abundant protein and it is the major structural component in most connective tissues 
including bone. One of the critical steps in collagen biosynthesis, which contributes to the 
functional integrity of the tissues, is the post-translational modifications including the 
hydroxylation of specific proline (Pro) and lysine (Lys) residues, glycosylation of specific 
hydroxylysine (Hyl) residues, and the formation of covalent intermolecular cross-links. 
Though several functions have been proposed for collagen glycosylation such as control of 
collagen fibrillogenesis (8-11,112) , cross-linking (38,118,121-124,168), remodeling (126-
133) collagen-cell interaction (148-149) (reviewed in section 1.6.3-1.6.8), the function is still 
not well defined due in part to the lack of clear understanding of the mechanism of this 
modification. 
In fibrillar collagens, glycosylation occurs at specific Hyl residues by hydroxylysyl 
galactosyltransferase (GT) (EC 2.4.1.50) and galactosylhydroxylysyl glucosyltransferase 
(GGT) (EC 2.4.1.66) resulting in the formation of galactosylhydroxylysine (G-Hyl) and 
glucosylgalactosylhydroxylysine (GG-Hyl) respectively. Recently, these enzymatic activities 
were found in the multifunctional enzyme, lysyl hydroxylase 3 (LH3), one of the collagen 
modifying enzymes in the lysyl hydroxylase (LH) family, encoded by PLOD3 (79-80,108).  
The GT and GGT activities of LH3 were identified by measuring the transfer of 
radiolabeled sugar moieties to Hyl residues in calf skin gelatin substrate (79-80). The 
biological significance of the GGT activity of LH3 in the biosynthesis of types IV and VI 
collagen has been demonstrated from the studies of LH3 deficient mice (69-70,99).  In 
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addition, defective GGT activity, resulting from four polymorphic nucleotides in the non-
coding region of PLOD3, was detected in a family with dominant epidermolysis bullosa 
simplex (DEBS) (101,154). In another recent finding, two heterozygous mutations in the 
PLOD3 coding region, have been associated with a rare syndrome of congenital 
malformations affecting several connective tissues and organs (100).   As for the GT activity 
of LH3, the data has been somewhat conflicting and the biological significance is still not 
clearly understood. This activity could be performed by recently reported novel enzymes, 
glycosyltransferase 25 domain 1 and 2 encoded by GLT25D1 and GLT25D2, respectively 
(81) (reviewed in section 1.6.2).  
It has been reported that altered collagen glycosylation is associated with bone 
disorders (155-156,158-160,165-166,169) (reviewed in section 1.7). However, the role of 
LH3 in type I collagen modification and bone biology have not been investigated. 
In order to elucidate the function of LH3 for bone type I collagen, we have employed 
an in vitro loss-of-function approach in mouse osteoblast-like cell line, MC3T3-E1 (MC) by 
generating single cell-derived clones stably suppressing LH3. Type I collagen produced by 
the clones were analyzed for the extent of modifications (e.g. GG-Hyl, G-Hyl and free Hyl) 
and fibrillogenesis.  In addition, recombinant LH3-V5/His fusion protein was generated and 
its enzymatic functions were investigated by means of a newly developed high performance 
liquid chromatography (HPLC)-based glycosyltransferase activity assay. 
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Experimental Procedures 
Cell Lines and Culture Conditions 
MC3T3-E1 subclone #4 (MC), a well characterized nontransformed mouse 
osteoblast-like cell line (170) was purchased from American Type Culture Collection (CRL-
2593). The cells were grown in α-MEM (Invitrogen, Carlsbad, CA, USA) containing 10% 
FBS (Invitrogen) and supplemented with 100 U/ml penicillin G sodium, 100 g/ml 
streptomycin sulfate. 293 HEK (Human Embryonic Kidney) cells were purchased from 
Clontech (Mountain View, CA, USA). The cells were maintained in Dulbecco’s Modified 
Eagle Media (DMEM; Invitrogen) with high glucose (4.5g/l) and same supplements as 
described above. Both cell lines were cultured in a 5% CO2 atmosphere at 37ºC and the 
medium was changed twice a week. 
 
Expression of Plod Family, Glt25d1 and Glt25d2 in MC cells 
MC cells were plated at a density of 2x10
5
 cells/35mm dish and after 48 hours, total 
RNA was extracted with TRIzol reagent (Invitrogen), and two µg of total RNA was 
converted into cDNA by using the Omniscript Reverse Transcriptase kit (Qiagen, Valencia, 
CA, USA). Quantitative real-time PCR was performed using the sequence specific primer for 
LH1 (Plod1; ABI assay number: Mm00599925_m1), LH2 (Plod2; Mm00478767_m1), LH3 
(Plod3; Mm00478798_m1), Glt25d1 (Glt25d1; Mm00600638_m1), and Glt25d2 (Glt25d2; 
Mm00625070_m1). The reactions were prepared and analyzed in triplicates by the ABI 
Prism 7000 Sequence detection system (Applied Biosystems, Foster city, CA, USA). The 
mRNA expression level of LH3 relative to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH; ABI assay number 4308313) was analyzed by the 2
-ΔΔCT
 method (171). 
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Generation of short hairpin expressing plasmid targeting Plod3 
The target sequences for suppression of Plod3 were designed by siDesign Center 
website (Dharmacon RNAi technologies). The three highest ranked targets were selected 
(si#1 AGAAGGAAATGGAGAAATA [start position 956], si#2 
CCACAAGGGTGTAGATTAT [2715], si#3 GAACAAAACAGGAAGGTAA [1897]) and 
converted into short hairpin oligonucleotide sequences specific for pSilencer2.1 vector by the 
siRNA converter (Ambion, www.ambion.com). This method added BamHI and HindIII 
restriction site overhangs at the 5’ end of the sense and antisense oligonucleotide 
respectively, to facilitate efficient directional cloning into the pSilencer vectors. The two 
complimentary 55-mer oligonucleotides for each target were synthesized (MWG Eurofins, 
Huntsville, AL, USA), and annealed in the annealing buffer (10mM Tris pH 7.5-8.0, 
50mMNaCl, 1mM EDTA) according to the condition described in the instruction manual for 
pSilencer2.1 vector. The annealed oligonucleotides were then ligated into the pSilencer2.1-
U6/neo vector (Ambion, Austin, TX, USA, a generous gift from Dr. Franck Polleux, 
Neuroscience Center, University of North Carolina at Chapel Hill), linearized with BamHI 
and HindIII restriction enzymes digestion, and transformed into bacteria competent cells. The 
clones with 100% nucleotide sequence accuracy (Eton Bioscience, Durham, NC, USA) for 
each target (Sh1, Sh2, and Sh3) were selected and tested for their suppression efficiency by 
transient transfection into MC cells using FuGENE6 transfection reagent (Roche, 
Indianapolis, IN, USA). The non-transfected MC cells and those transfected with the original 
pSilencer2.1-U6/neo plasmid (EV; encoding a hairpin siRNA sequence not found in any 
genome database) were used as controls. After 48 hours, total RNA was extracted, converted 
into cDNA and analyzed for the expression of Plod3 by quantitative real-time PCR as 
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described above. The suppression efficiency among the different ShRNA target sites was 
then compared in percentage relative to the controls. 
 
Generation and characterization of MC single cell-derived clones stably suppressing LH3  
MC cells were transfected with the selected pSilencer2.1-U6/neo-Plod3 plasmid by 
using FuGENE6 transfection reagent (Roche).  After 48 hours, the transfected cells were 
trypsinized, plated at a low density and maintained under constant selection with 400 μg/ml 
G418 sulfate (G418; Mediatech, Inc., Manassas, VA, USA).  Several single cell-derived Sh 
clones were isolated by cloning rings and maintained in α-MEM, 10% FBS, 100 units/ml 
penicillin, 100 μg/ml streptomycin along with 400 μg/ml G418. The single cell-derived EV 
clones were isolated and maintained in the same manner as described above. The selected Sh 
clones were then characterized by comparing the level of Plod3 expression to those of the 
EV clone and the non-transfected MC cells, by using quantitative real-time PCR. Three to six 
Sh clones with different levels of Plod3 suppression were then characterized for its effects on 
the mRNA expression of LH1 (Plod1; ABI assay number: Mm00599925_m1), LH2 (Plod2; 
Mm00478767_m1), Glt25d1 (Glt25d1; Mm00600638_m1), and type I collagen α2 chain 
(Col1A2; Mm00483888_m1). The effect on cell proliferation was assessed by using CellTier 
96 MTS assay (Promega, Madison,WI, USA) as previously reported (172).  
 
Generation of anti-mouse LH3 antibody 
Polyclonal rabbit anti-mouse LH3 antibody was commercially generated (Bethyl 
Laboratories, Inc., Montgomery, TX, USA) by immunization with the HPLC purified, 
synthetic peptide, corresponding to the amino acids 357 to 371 (FSAVKLVGPEEALSA) 
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conjugated to KLH. The agarose-bound peptide was used for the affinity purification of the 
antibody from the hyperimmune rabbit sera obtained from the immunized animal. The 
sensitivity and specificity of the antibody was determined by Western Blot analysis of 
purified recombinant LH3-V5/His tagged protein, as described below.  
 
Immunoprecipitation and Western Blot analysis 
To determine the LH3 protein level, the Sh clones and the controls were plated onto 
35mm dishes at a density of 3x10
5
 cells/dish. After culturing for 7days, the cultured medium 
was collected and the cells were washed with PBS, lysed with lysis buffer containing 150 
mM NaCl, 20 mM Tris-HCl, pH 7.5, 10 mM EDTA, 1% TritonX-100, 1% deoxycholate, 
1.5% aprotinin, and 1 mM phenymethylsulfonylfluoride, centrifuged and the supernatant 
collected. The cultured medium was incubated overnight with anti-LH3 antibody (see 
above), followed by incubation with protein G-sepharose 4B conjugate beads (Invitrogen) for 
30 minutes, washed with lysis buffer, solubilized in SDS sample buffer (100 mM Tris-HCl, 
pH 8.8, 0.01% bromphenol blue, 36% glycerol, and 4% SDS) in the presence of 10 mM 
dithiothreitol, and separated by 4–12% NuPAGE Bis-Tris gel (Invitrogen). As for the cell 
lysates, the total protein concentration was measured by the DC protein assay kit (Bio-Rad 
Laboratories, Hercules, CA, USA) according to the manufacturer’s protocol, and 20 µg of 
total protein was directly applied to 4-12% NuPAGE Bis-Tris gel. The separated proteins 
were transferred to a polyvinylidene fluoride (PVDF) membrane (Immobilon-P; Millipore 
Corp., Bedford, MA, USA) and subjected to Western blot analysis with anti-LH3 antibody 
followed by incubation with anti-rabbit IgG conjugated to alkaline phosphatase (AP) 
secondary antibody (Thermo Scientific, Rockford, IL, USA).  The immunoreactivities were 
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detected with AP conjugate substrate kit (BioRad Laboratories). Equal protein loading of cell 
lysate was confirmed by Western blotting with anti-β-actin antibody.  
 
Purification of type I collagen 
The same number of cells of MC, EV and Sh clones were plated on to 10-cm dishes 
and maintained with twice-a-week change of medium (α-MEM , 10% FBS, 100units/ml 
penicillin, 100μg/ml streptomycin). When the cells reached confluence, 50μg/ml of ascorbic 
acid was added and cultured for at least 2 weeks, the cell/matrix layer was then collected and 
subjected to type I collagen extraction as previously described (173). Briefly, the 
cell/matrices were washed with PBS and cold distilled water, lyophilized and subjected to 
limited pepsin digestion (20% w/w) in 0.5N cold acetic acid with constant stirring at 4˚C for 
24 hours. After ultracentrifugation at 35,000 rpm for 2 hours, the supernatant was collected 
and type I collagen was precipitated with 0.7M NaCl. The precipitate was then reconstituted 
with 0.5N acetic acid, dialyzed against cold distilled water for 48 hours at 4˚C and 
lyophilized. Collagen solution was prepared by reconstituting the lyophilized collagen in 
0.01N acetic acid to the concentration of 0.5 µg/µl. The purity of type I collagen obtained 
from the control cells and clones was assessed by 6%Tris-Glycine gel electrophoresis 
(Invitrogen) stained with Coomassie Brilliant Blue (CBB) and by amino acid analysis (see 
below).  
 
In vitro fibrillogenesis assay 
 The procedure previously described (12) was slightly modified for the use of a 96-
well microtiter plate. Briefly, lyophilized type I collagen purified from each group was 
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redissolved in 0.01 M acetic acid at a concentration of 0.2µg/µl. The reactions were prepared 
in triplicates, in a 96-well microtiter plate pre-cooled on ice, containing the reaction buffer 
(140mM NaCl, 30mM sodium phosphate (PBS) at pH7.3) (174)  and purified type I collagen 
in the ratio of 1:1 (v/v), and placed in the Powerwave X 340 spectrophotometer (BioTek, 
Winooski, VT, USA) equilibrated at 37˚C. Formation of collagen fibrils was monitored by 
measuring the absorbance at 400nm (turbidity), at 1000 seconds intervals for 15 readouts. 
The turbidity-time curve was plotted and the differences in the rate of collagen fibril 
formation and the potential fibril diameter among the clones and the controls were compared. 
 
Purification of GG-Hyl and G-Hyl standards  
Natural marine sponge was used to isolate GG-Hyl residues (175-176). Fifty 
milligrams of sponge was pulverized in a Spex freezer mill (SPEX CertiPrep, Metuchen, NJ, 
USA), subjected to base hydrolysis with 2N NaOH in sealed polypropylene tubes flushed 
with N2 gas, and incubated at 110°C for 22 hours. The hydrolysate was acidified to a ~pH 3 
with 2N HCl, and filtered. It was then applied to a standardized molecular sieve column 
filled with Bio-Gel® P-2 resin (Bio-Rad Laboratories) equilibrated in 0.1N acetic acid buffer 
at a flow rate of 0.7ml/min and monitored by absorbance at 214 nm (177). Several collagen 
cross-link standards were used as molecular weight standards to isolate the GG-Hyl (MW: 
487 Da) -enriched fractions. The GG-Hyl residues eluted slightly earlier than the Pyr 
standard (MW: 428 Da). In order to generate the monoglycosylated form, G-Hyl, the purified 
GG-Hyl was subjected to mild acid hydrolysis with 0.8N HCl at 110°C for 1 hour.  The 
resulting G-Hyl was purified using the P-2 column as described above. The identities of the 
purified GG-Hyl and G-Hyl were confirmed by mass spectrometry. 
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Mass Spectrometry analysis of glycosylated hydroxylysine standards 
The fraction containing GG-Hyl, G-Hyl and free Hyl from the mild acid hydrolysis 
was analyzed by nano-ESI-MS on a Waters QTof Global mass spectrometer (Milford, MA). 
A 1:100 dilution (v/v) in a solvent mixture containing 50 % methanol in deionized water 
acidified with 0.1 % formic acid was used for flow injection analysis. The mass spectra were 
acquired over the mass range m/z 150-1000. The source parameters employed were as 
follows: capillary voltage – 3.5 kV, cone voltage - 80 V, collision energy 10 V. The MS/MS 
spectra were acquired using targeted analysis of the ions of interest. The collision energy was 
optimized for each ion, ranging from 10 to 15 V for the singly protonated ion of G-Hyl, and 
from 15-25 V for the singly protonated ion of GG-Hyl. 
 
Quantification of GG-Hyl, G-Hyl and Free Hyl 
Lyophilized collagen samples were hydrolyzed with 6N HCl (Sequenal Grade; 
Thermo Scientific) in vacuo after flushing with N2 at 110°C for 22 hours. The hydrolysates 
were subjected to amino acid analysis on a Varian 9050 HPLC system (9050/9012; Varian 
Associates Inc., Palo Alto, CA, USA),  equipped with a strong cation exchange column 
(AMINOSep #AA-911, Transgenomic, Omaha, NE, USA) (173). The level of total Hyl (GG-
, G- and free Hyl) in a collagen molecule was calculated based on the value of 300 residues 
of Hyp per collagen molecule. 
To determine the level of glycosylated Hyl, lyophilized collagen samples were also 
subjected to base hydrolysis and the hydrolysates were prepared in the same manner as 
described above. Then the GG-, G- and free Hyl in the hydrolysates were separated and 
quantified with a specific gradient program (Table 3.1) developed on the same HPLC system 
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mentioned above. Separation of the different Hyl species from one another and from other 
amino acids was achieved in 75 minutes. The color factor of Hyl was used to calculate the 
quantity of GG-Hyl and G-Hyl (141,178-179). Since Hyp is partially degraded during base 
hydrolysis, the amount of total Hyl/collagen was determined by acid hydrolysis (see above). 
Based on the ratio of the three Hyl forms (GG-, G- and free Hyl) and the total Hyl values 
obtained from acid hydrolysis, each form of Hyl was quantified as residues/collagen 
molecule.  
 
Molecular cloning of mouse LH3 cDNA  
Total RNA was isolated from MC cells using TRIzol reagent (Invitrogen) according 
to the manufacturer’s protocol. The first-strand cDNA was synthesized from 2 g of total 
RNA by means of the Omniscript Reverse Transcriptase Kit (Qiagen). Specific primers for 
the coding sequence of mouse LH3 (GenBank accession NM011962) were designed as 
follow: forward primer including restriction enzyme sequence for EcoRI,  
5’_GCGAATTCCGGGCCTGGGTGTAGCCT_3’; and reverse primer including the 
sequence for XhoI, 5’_GCCTCGAGGGGGTCAACAAAGGACACCATG_3’. PCR 
amplification was performed by the ProofStart DNA polymerase (Qiagen) with an annealing 
temperature of 60.0°C for 40 cycles. After digesting the PCR products with EcoRI and XhoI 
restriction enzymes, the inserts were ligated into the pcDNA3.1/V5/His_verA vector 
(Invitrogen) generating the pcDNA3.1/LH3-V5/His constructs. The molecular size of the 
ligated insert of 2389 bp was analyzed by EcoRI and XhoI restriction enzymes digestion 
followed by 2% agarose gel electrophoresis. Plasmids containing digested inserts were 
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sequenced at the UNC-CH DNA Sequencing Facility and showed 100% homology to the 
mouse LH3 in the database. 
 
Purification of LH3-V5/His fusion protein 
293 HEK cells were transfected with pcDNA3.1/LH3-V5/His plasmid using FuGENE 
6 transfection reagent (Roche) according to the manufacturer’s instructions, and the cells 
were cultured in the presence of 400 g/ml of G418 (Mediatech, Inc.) to isolate stably 
transfected single cell-derived clones. Based on Western Blot analysis with anti-V5-AP 
antibody, the clone that synthesized the highest level of LH3-V5/His protein was selected 
and cultured to collect the cultured medium. LH3-V5/His protein was purified using a nickel-
nitrilotriacetic acid agarose resin (Qiagen), and eluted with elution buffer containing 0.2M 
NaCl, 0.1M glycine, 0.1% glycerol, 50mM urea, 20mM Tris, and 0.05M histidine, pH 7.5.  
The purified proteins were pooled, dialyzed, concentrated with centrifugal filter with MWCO 
30,000 (Centricon; Millipore Corp.), and stored at -20 °C until use. The protein concentration 
was measured using a DC protein assay kit (Bio-Rad Laboratories) and the purity of the 
purified LH3-V5/His protein was determined by 4-12% NuPAGE Bis-Tris gel and CBB 
staining. In order to confirm its identity, the gel-resolved proteins were transferred to a PVDF 
membrane (Immobilon-P; Millipore Corp.) and subjected to Western blot analysis with anti-
V5-AP antibody (Invitrogen) or anti-LH3 antibody (Bethyl Laboratories, Inc.) with or 
without the epitope peptide (CFSAVKLVGPEEALSA). The immunoreactivities were 
detected in the same manner as described above.  
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HPLC-based collagen glycosyltransferase assays  
Pepsinized bovine skin collagen solution (PureCol® 3mg/ml) was purchased from 
Advanced BioMatrix (Advanced BioMatrix, Tucson, AZ, USA). Denatured collagen 
substrate was prepared by incubating the PureCol® solution in distilled water at 60°C for 30 
minutes and rapidly cooled on ice before use. The PureCol® solution without heat 
denaturation was used as a native collagen substrate. The assay for GT or GGT reaction was 
performed in pre-cooled 0.65ml microcentifuge tubes containing 120g native or denatured 
collagen substrate, 60M UDP-Glc or UDP-Gal (Calbiochem / EMD Chemicals, Gibbstown, 
NJ, USA), 12l of reaction buffer (16.7mM MnCl2, 1mM DTT, 2mg/ml BSA, 0.1M sodium 
bicarbonate buffer pH7.8), recombinant LH3-V5/His protein and distilled water in a total 
volume of 100µl. The tubes were incubated at 37°C for 45 minutes and the reactions were 
terminated by placing the tubes on ice. The reaction products were dried by speed vacuum 
centrifugation (Savant Instrument Inc., Hicksville, NY, USA), hydrolyzed with base and 
analyzed for the level of GG-Hyl, G-Hyl and free Hyl as described above. 
 
Statistical analyses 
Statistical analyses were performed using Jmp®8.0 software (SAS Institute Inc., 
Cary, NC, USA). Statistical differences were determined by Kruskal-Wallis one-way 
analysis of variance, means comparison to the controls by Dunnett’s Method and means pair 
comparison by Student’s t test. The data were presented as means ± SD and a p value less 
than 0.05 was considered significant. 
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Results 
 
Expression of Plod family, Glt25d1 and Glt25d2 in MC cells 
At 48hrs of MC cells culture, the expressions of Plod1-3 and Glt25d1-2 were 
analyzed by quantitative real-time PCR. By normalizing to GAPDH, the results showed that 
Plod3 was expressed at the highest level among the Plod family. In addition, Glt25d1 was 
highly expressed in MC cells while Glt25d2 was undetectable (Figure 3.1). The expression of 
Plod3 and Glt25d1 remained high and that of Glt25d2 was undetectable up to 4 weeks of 
culture (data not shown). Among these genes, the highest expression was constantly observed 
for Plod3 (p < 0.05). 
 
Generation of clones stably suppressing Plod3 
By transiently transfecting MC cells with pSilencer2.1-U6/Neo plasmids encoding 
hairpin oligonucleotides targeting three different sites in Plod3, the expression levels of 
Plod3 relative to GAPDH from all three targets were significantly suppressed. In comparison  
 
Figure 3.1) Gene expression of Plod 
and Glt25 families in MC cells. After 
48 hours of culture of MC cells, the 
mRNA expression of Plod1, Plod2, 
Plod3, Glt25d1 and Glt25d2 relative to 
internal control, GAPDH, was analyzed 
by quantitative real time PCR. Note that 
the expression of Glt25d1, not Glt25d2, 
is expressed in MC cells. Error bars 
indicate mean ± SD of three independent 
experiments. Significantly different from 
†: Plod1, #: Plod2, ‡: Plod3, ұ: Glt25d1, 
§: Glt25d2. (p < 0.05)  
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to the non-transfected MC cells (100%), the expression levels of Plod3 in Sh1, 2 and 3 were 
20%, 22% and 46%, respectively.  The Plod3 expression in the transfected control (EV) was 
~80% of that of MC cells. The suppression levels of Plod3 among the different targeting 
sequences were essentially the same when normalized to Col1A2 (data not shown). The 
targeting sequence number one (Sh1), showing the most suppression, was selected to 
generate single cell-derived clones stably suppressing LH3 by constant selection with G418. 
Several clones were isolated and characterized.  
 
Characterization of Sh1-derived clones stably suppressing LH3 
Three representative clones (Sh1-1, 1-2 and 1-3) stably suppressing Plod3, that 
exhibited similar cell proliferation patterns to that of controls, were selected for further 
characterization. Quantitative real-time PCR analyses, from three independent experiments, 
 
Figure3.2)  Gene expression of Plod family and Glt25d1 in single cell-derived Short hairpin (Sh) 
clones. After 48 hours of culture, real time PCR was performed to determine the suppression levels of 
Plod3 in the single cell-derived Sh clones and its potential effects on Plod1, Plod2 and Glt25d1 
expression. The mRNA expression was normalized to the internal control, GAPDH. Only the 
expressions of Plod3 in the Sh clones were significantly different when compared to the controls, MC 
and EV. Error bars indicate mean ± SD of three independent experiments. *, significantly different 
(p<0.0001) from MC and EV. 
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showed statistically significant decreases in the expression of Plod3 in all Sh clones 
(p<0.0001), compared to the EV and MC controls (Figure 3.2). The higher expression of the 
Plod3 in the EV clone compared to MC parental cell was constantly observed during the 
isolation and characterization of the EV clones, likely due to the effect of transfection. The 
effect of Plod3 suppression on the expression of the other Plod family members and Glt25d1 
was also investigated. When normalized to GAPDH, the expressions of Plod2 and Glt25d1 
were not significantly changed in all the three Sh clones when compared to the controls. 
Plod1 expression was also mostly unaffected except for Sh1-1 in that the expression of Plod1 
was slightly lower when compared to EV (p<0.05) but not significantly different from MC.  
The LH3 protein levels from the clones were assessed by direct Western blot analysis 
for the cell lysate and immunoprecipitation/Western blot analysis for the cultured medium 
(Figure 3.3). In Figure 3.3A, an immunoreactive band was observed at the expected 
molecular weight of LH3 at ~ 87kDa in the cell lysates of the controls and the Sh clones; 
however the intensity was decreased in all Sh clones. Comparable loading amounts of the 
cell lysates was confirmed by Western blotting detection of β-actin.  Figure 3.3B shows the  
 
 
Figure 3.3) The levels of LH3 protein produced by the Sh1 derived clones and controls 
A) Western blot analyses of cell lysates with anti-LH3 antibody and anti-β-actin antibody. Twenty µg 
of total protein from each sample was loaded. B) Immunoprecipitation-Western blot analyses of the 
cultured media with anti-LH3 antibody. The intensity of the immunoreactive bands from Sh1-1,-2, 
and-3 were significantly lower than that of the controls, MC and EV, in both cell lysate and cultured 
media. WB: Western blotting, IP: Immunoprecipitation, Ab: Antibody. 
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result of immunoprecipitation followed by Western blot analysis with anti-LH3 antibody 
from the cultured media collected from the clones and controls. Compared to the controls, all 
three Sh clones showed lower intensity of the immunoreactive bands observed at ~91 
kDa.The apparent molecular weight of these bands was slightly higher than those observed in 
the cell lysate (~87 kDa). This observation is consistent with a previous report showing that 
the extracellular LH3 protein is modified by asparagine-linked glycosylation during the 
secretion process (76). Together, it is evident that suppression of Plod3 by short hairpin RNA 
expression plasmid resulted in decreases in the levels of LH3 protein, both intra- and 
extracellularly. 
 
Fibril formation kinetics of purified type I collagen  
Type I collagen without telopeptides was purified from 2 weeks cell/matrix layer of 
the MC, EV and Sh1-1, -2 and -3. The purity of the collagens was determined by 6% Tris-
 
Figure 3.4) In vitro fibrillogenesis assay  
After 2 weeks of culture, type I collagen without telopeptides was purified from the cell/matrix layers 
of MC cells, Sh (1-1, 1-2 and 1-3) and EV clones. Twenty µg of purified collagens (0.2µg/µl) were 
incubated in a 96-well microtiter plate at 37°C and the 400nm absorbance (turbidity) was measured 
(see Experimental procedures for details). The kinetics of the collagen fibrils formation are shown as 
a turbidity-time plot. 
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Glycine gel electrophoresis, where only the collagen associated chains (α chains with some β 
and γ components) were identified (data not shown). In addition, amino acid analyses 
showed approximately 100 residues Hyp and ~340 residues of glycine/1000 amino acids in 
MC, ShEV and all the Sh clones indicating a high level of collagen purity.  The purified 
collagen from the clones and controls were subjected to an in vitro collagen fibrillogenesis 
assay to compare the fibril formation kinetics among the groups. Figure 3.4 showed the 
turbidity-time curve plotted from the 400nm absorbance measured over time. Comparing to 
the controls, MC and EV, the collagen from  all three Sh clones showed shorter lag time and 
higher turbidity plateau indicating faster rate of fibril formation and potentially larger 
collagen fibrils diameter, respectively (180). The result shown is the representative of several 
independent assays. 
 
Purification and NanoESI-Qtof analysis of GG-Hyl and G-Hyl standards 
 The GG-Hyl and G-Hyl residues were purified from the base hydrolysate of natural marine 
sponge by molecular sieve chromatography.  The identity of the purified GG-Hyl residues 
was indirectly confirmed through the conversion of GG-Hyl into G-Hyl and free Hyl by mild 
acid hydrolysis. The upper panel in Figure 3.5A shows the chromatogram of the potential 
GG-Hyl residue separated on a strong cation-exchange column detected by the ninhydrin-
derivatization method. The program was specifically developed to separate GG-, G- and free 
Hyl from one another and from other known amino acids. The lower panel shows the same 
compound after the mild acid hydrolysis demonstrating a decrease in the amount of the 
potential GG-Hyl and the appearance of two additional ninhydrin-positive peaks eluting at 
later time points. The double peak eluting at ~70 minutes is consistent with the elution of  
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Figure 3.5) Purification and identification of glycosylated Hyl standards.  
A) Upper panel: ion-exchange chromatogram of potential GG-Hyl residues isolated from a P-2 
column; Lower panel: ion-exchange chromatogram of the same compound after mild acid hydrolysis 
showing the conversion into free Hyl and an intermediate product, potentially G-Hyl. B) Mass 
spectrum of the mixture of Hyl, G-Hyl and GG-Hyl from the amino acid analysis, showing the 
molecular ions corresponding to each species.  C-D) MS/MS spectra of the ions of m/z 487.221 and 
325.167, confirming the structures of GG-Hyl and G-Hyl respectively. Hyl: hydroxylysine, G-Hyl: 
galactosyl Hyl, GG-Hyl: glucosylgalactosyl Hyl. 
 
the Hyl standard.  The double peak eluted at ~47 minutes is most likely the intermediate 
product in the conversion of GG-Hyl into free Hyl, i.e. G-Hyl residue, based on the physico-
chemical characteristics of the molecule and from previous reports (176,178,181-182).  
To confirm the identity, the mild acid hydrolysate containing a mixture of the 
potential three Hyl species was analyzed on a QTof Global mass spectrometer by nanoESI. 
The most abundant ion in the MS spectrum shown in Figure 3.5B, observed as m/z 487.209 
(1+), was assigned to hydroxylysine modified with dihexose, GG-Hyl. The ion 
corresponding to the G-Hyl species was observed as m/z 325.161. Unmodified Hyl was 
observed as the singly protonated ion of m/z 163.105. The structural characterization of each  
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compound was performed by MS/MS, shown in Figures 3.5C and 3.5D. The fragment ions 
observed in the MS/MS spectrum of the ion of m/z 487.209, obtained with a collision energy 
of 20 V, are characteristic for the CID spectra of glycoconjugates, confirming the structure 
GG-Hyl (Figure 3.5C). The fragment ions of m/z 325.165 and m/z 163.103, assigned to Y1 
and Y0 (183) are derived from the subsequent neutral loss of each hexose from the non-
reducing end, whereas the ion of m/z 367.178, assigned to 
0,2
X1 resulted from a cross-ring 
cleavage in the first monosaccharide ring. The ion of m/z 205.116 is most likely formed in a 
secondary fragmentation event, by cross-ring cleavage within the Y1 fragment. This 
hypothesis is supported by the fact that, by increasing the collision energy, this ion is 
observed with higher relative abundance. The fragment ions observed in the CID spectrum of 
the ion of m/z 325.167, shown in Figure 3.5D, were obtained using collision energy of 15 V. 
The most abundant ion, m/z 163.101, Y0, is derived from the fragmentation of G-Hyl from 
the non-reducing end. 
 
Quantification of GG-Hyl, G-Hyl and Free Hyl 
To separate and quantify the level of GG-Hyl, G-Hyl and free Hyl, a new program 
was developed on the amino acid analysis system in our laboratory by modifying the buffer 
gradient previously reported (173), shown in Table 3.1. The separation of the glycosylated 
Hyl and the other amino acids standard are shown in Figure 3.6. This specific program can be 
used to analyze base hydrolysates of collagens, as the carbohydrate units are retained under 
these conditions. Figure 3.7 shows the levels of the different Hyl species in type I collagen 
purified from control cells and clones, analyzed in triplicates. The results revealed that there 
was a significant decrease in the level of GG-Hyl with a concomitant level increase of G-Hyl  
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Table 3.1 HPLC gradient system for the separation of GG-Hyl, G-Hyl and free Hyl 
 
 
Figure 3.6) HPLC elution profile of GG-, G- and free Hyl relative to other amino acids.         
Three-letter abbreviation is used to indicate amino acids. 
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in collagen from Sh clones, while the levels of free Hyl remained comparable between the Sh 
clones and the controls, MC and EV. This modification profile was also confirmed in type I 
collagen purified from the other two independent sets of cultures. This clearly indicates that 
the major role of LH3 for type I collagen in osteoblasts is to transfer glucose units to G-Hyl 
residues. 
 
Purification of recombinant LH3-V5/His fusion protein 
To confirm the glycosyltransferase activity of LH3, recombinant LH3-V5/His fusion 
protein was purified from the cultured medium of 293 HEK cells. An aliquot from the 
collected fractions were analyzed by 4-12% NuPAGE Bis-Tris gel stained with CBB and by 
Western blot analyses (Figure 3.8). By CBB staining, a major single band was observed at 
~96kDa, consistent with the expected molecular weight of LH3-V5/His fusion protein (91 
kDa of LH3 + 5 kDa tag) (lane 1). The identity of the purified protein was further confirmed 
by Western blot with anti-V5 (lane 2) and anti-LH3 antibodies (lane 3). When peptide 
blocking was performed, the intensity of the immunoreactive bands to anti-LH3 antibody  
 
 
 
 
Figure 3.7) The glycosylation levels 
of Hyl residues in the purified type I 
collagen synthesized by Sh1 clones 
and controls.  
The levels of GG-Hyl, G-Hyl and free 
Hyl are shown as residues/mol 
collagen. Error bar indicate mean ± 
SD of triplicate analyses of the 
hydrolysates.  
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was decreased indicating the competitive binding of the peptides to anti-LH3 antibody (lane 
4). The fractions were then pooled, dialyzed and concentrated. 
 
Glycosyltransferase activity of LH3-V5/His fusion protein 
The results of the GT and GGT activity assays of LH3-V5/His fusion protein with 
bovine skin collagen substrate are shown in Figure 3.9. When LH3-V5/His fusion protein 
was incubated with denatured collagen substrate, the level of GG-Hyl was significantly 
increased with a concomitant decrease in the level of G-Hyl (Figure 3.9A) leading to a 
reverse in the GG-Hyl/G-Hyl ratio (Figure 3.9B). However, the transfer of galactose units to 
free Hyl was not observed as the GGHyl/GHyl ratio did not change (Figure 3.9B). When 
native bovine skin collagen was used as a substrate, the GGT activity was not observed 
(Figure 3.9A-B). To confirm the specificity of the enzymatic functions, the dose-effect of 
LH3-V5/His protein was examined (Figure 3.9C). With denatured collagen substrate, the 
change in the GG-Hyl/G-Hyl ratio and the dose-effect were observed only for the GGT 
activity but not the GT activity. The GGT activity was readily detected with the amount of 
LH3-V5/His protein as low as 0.1% of the collagen substrate (w/w) indicating strong potency  
 
 
Figure 3.8) Characterization of recombinant LH3-
V5/His tagged protein.  
Purified LH3-V5/His protein was subjected to 4-12% 
NuPAGE Bis-Tris gel and stained with CBB (lane 1), 
WB analysis with anti-V5 antibody (lane 2), anti-LH3 
antibody (lane 3) and anti-LH3 antibody with peptide 
block (lane 4). The major band at the level of ~96 
kDa showed immunoreactivities to both anti-V5 and 
anti-LH3 antibody.  
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of the recombinant LH3-V5/His fusion protein as an enzyme (data not shown). When native 
collagen was used as a substrate, the GG-Hyl/G-Hyl ratio was not changed with any levels of 
LH3-V5/His protein examined (Figure 3.9C). Similar results were observed when rat tail 
tendon collagen was used as a substrate for the GT and GGT activity assays (data not 
shown). The results shown here indicate that the purified LH3-V5/His protein is 
enzymatically active with a specific function of glucosylation of G-Hyl residues, and suggest 
that the specific substrates for LH3 are the collagen α-chains rather than the native collagen 
 
Figure 3.9) HPLC-based glycosyltransferase activity assays of recombinant LH3-V5/His against 
denatured and native type I collagen. The transfer of galactose or glucose units (GT or GGT 
respectively) by the purified LH3-V5/His protein was performed with bovine skin collagen 
(PureCol®) substrate. The base hydrolysates of the reaction products were analyzed for the level of 
G-Hyl or GG-Hyl by HPLC (see Figure 3.6). A) Percentage of GG-Hyl, G-Hyl and free Hyl, B) GG-
Hyl/G-Hyl ratios of the reaction products, C) GG-Hyl/G-Hyl ratios of the GGT and GT activity 
assays using increasing levels of LH3-V5/His proteins with denatured or native collagen substrate. 
GT: hydroxylysyl galactosyltransferase, GGT: galactosylhydroxylysyl glucosyltransferase, LH3: 
LH3-V5/His protein. Error bars indicate mean ± SD from triplicate assays. *, significantly different 
from PureCol (in A & B) and from No LH3 (in C), p < 0.05. 
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molecules, which is consistent with previous reports showing that the triple helical 
conformation of collagens inhibited further post-translational modifications (77-78).  
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Discussion 
 
During the past decade, several reports have shown the unique features of LH3, i.e. its 
multifunctionality (LH, GT and GGT activities) (79-80,108,184) and its intra- as well as 
extracellular localization (76). The critical importance of this enzyme for the connective 
tissue integrity was clearly demonstrated through the gene knockout mouse study and others 
(69,99-101). The enzymatic functions of LH3 were shown through in vitro activity assays 
using lysates from SF9 cells transfected with LH3 expression plasmid, cell-free translation or 
purified recombinant LH3 protein as the enzyme source (79-80,108,184). The GGT activity 
of LH3 and its biological significance have been well demonstrated, however, data regarding 
the GT activity of LH3 has been somewhat conflicting (70,79-80). Recently, Schegg et al 
have reported the cloning of novel collagen galactosyltransferase enzymes, GLT25D1 and 
GLT25D2, and showed that these enzymes were capable of transferring galactose units to 
free Hyl residues in collagen while LH3 was not (81). However, direct measurements of the 
amount of G-Hyl or GG-Hyl residues were rarely performed in the assays used in the past. In 
this study, we have successfully purified the G-Hyl and GG-Hyl standards from natural 
marine sponge and developed a specific HPLC program which allowed us to effectively 
separate and quantify the levels of GG-Hyl, G-Hyl and free Hyl residues in the base 
hydrolysate of the collagen samples.  
Type I collagen is the major collagen type in most connective tissues including skin, 
bone and tendon. However, little is known about the role of LH3 in this major fibrillar 
collagen at present. In this study, by employing the short hairpin RNA technique in mouse 
osteoblasts, we have successfully generated single cell-derived clones stably suppressing 
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LH3, and characterized its effect on type I collagen post-translational modifications.  Our 
data demonstrated that the major function of LH3 is to glucosylate G-Hyl residues in type I 
collagen. The simultaneous increase in the level of G-Hyl residues observed from the LH3 
Sh clones is most likely the result of diminished level of glucose transfer by LH3 
suppression. The gene expression of GLT25D1, another potential galactosyltransferase, was 
unaffected by LH3 suppression. In addition, the levels of free and total Hyl residues in the 
purified type I collagen were essentially unchanged among the Sh clones and controls 
suggesting that the LH activity of LH3, if any, is minimal for bone type I collagen. In the 
past years, several groups have tried to determine the sequence or collagen type specificity 
for the activities of LH isoforms (55,62-70). The results from these studies indicated that 
there are no strict collagen types or sequence requirements for the individual LH isoforms. It 
was suggested that LH2b, the major isoform of LH2 in bone, mainly hydroxylates Lys 
residues in the telopeptide regions, thus, determining the collagen cross-linking pathway (54-
55,62,71-72). In contrast, LH1 preferentially catalyzes the hydroxylation of Lys residues in 
the triple helical region of fibrillar collagen including those residues pairing with the 
telopeptidyl Hyl/Lys aldehydes to form the intermolecular cross-links (62,65-66,69,73). As 
for LH3, its contribution to Lys hydroxylation in the helical region of fibrillar collagen is still 
unclear (62,69-70). When the function of one isoform is impaired, compensatory 
mechanisms from the other two isoforms may occur, and may depend largely on the tissue-
specific expression of each isoform (68).  
In this study, the enzymatic function of LH3 as the main GGT but not GT was also 
confirmed by using the enzymatically active recombinant mouse LH3-V5/His fusion protein 
generated by 293HEK cells culture. By using HPLC, we could directly measure the levels of 
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GG-Hyl and G-Hyl in the reaction products of the GGT and GT activity assays. The 
specificity of the glucosylation activity of LH3-V5/His protein against denatured type I 
collagen was demonstrated by the dose dependent increase of GG-Hyl when increasing 
amounts of LH3-V5/His protein were used. Furthermore, no transfer of galactose was 
observed even with increasing amounts of LH3-V5 protein. This result is consistent with 
studies showing that the GT activity of LH3 protein is very low (79-80) or even undetectable 
(70,81) in contrast to the GGT activity. As for the expressions of Glt25d1 and 2, only the 
former isoform was detected in MC cells. From our results and those recently reported by 
Schegg et al (81), it is likely that galactosylation of Hyl in bone type I collagen is catalyzed 
by Glt25d1, followed by subsequent glucosylation by LH3. 
The ability of recombinant LH3 to modify extracellular proteins (collagen or other 
proteins), as shown by GGT activity assay, indicated that LH3, unlike LH1 and LH2, is 
localized and functional in the extracellular space as well (76). However, the specific 
substrates for the extracellular function of LH3, such as collagens or proteins with 
collagenous sequences, have never been identified but assumed to be collagen. Interestingly, 
this finding contradicts with the earlier reports that triple helical conformation inhibits further 
modifications (77-78). Thus, it was proposed that in physiological temperature, there is a 
possibility of micro-unfolding of the triple helix which allows further modifications (76). In 
our study, when native bovine skin collagen was used as a substrate for the GGT activity 
assay, an increase in the level of GG-Hyl was not observed, as seen with denatured collagen 
substrate. This finding could suggest that the specific substrate for the enzymatic function of 
extracellular LH3 may not be type I collagen or that the secreted LH3 may play a different 
role.  
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From the current study, it is apparent that a decrease in glucosylation of G-Hyl in type 
I collagen significantly affects the collagen fibril formation kinetics observed in the in vitro 
fibrillogenesis assay. The collagen molecules with less glucosylation could self-aggregate 
faster and form thicker fibrils due in part to the lesser steric hindrance for the molecular 
packing. This result is consistent with other reports showing that the degree of collagen 
modification is inversely correlated to the rate and diameter size of collagen fibrils formed in 
vitro (8-9,185).  
It has been shown that one of the major cross-linking sites in the helical region of 
type I collagen (residue 87 of α1 and α2 chains) are mainly di-glycosylated (113-
116,118,123,168) (reviewed in Table 1.2). Thus, further studies are warranted to investigate 
the potential effects of the pattern (di- vs, mono-glycosylation) and extent of glycosylation on 
cross-link formation and maturation.  
Taken together, this study shows that, by manipulating the LH3 gene expression in 
mouse osteoblasts, the major function of LH3 is to transfer glucose units to G-Hyl residues in 
the α chains of bone type I collagen. This result has also been corroborated with the HPLC-
based glycosyltransferase activity assays, using recombinant LH3-V5/His fusion protein. The 
significant decrease in the transfer of glucose units, through LH3 suppression, results in the 
change in the in vitro collagen fibril formation kinetics. It can be concluded that the levels 
and types of Hyl glycosylation, and possibly, its loci in type I collagen are indeed critical for 
proper formation of collagen fibrils. 
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Abstract 
Recently, by employing the short hairpin RNA technology, we have successfully 
generated single cell-derived clones stably suppressing lysyl hydroxylase 3 (LH3) (Sh 
clones) in mouse osteoblast cell line, MC3T3-E1 (MC), and demonstrated the function of this 
enzyme as glucosyltransferase in type I collagen. To further elucidate the biological 
significance of this specific post-translational modification in type I collagen, we 
characterized the collagen produced by Sh clones and controls. Mass spectrometry analysis 
identified the specific glycosylation sites at α1-87 (but not α2-87), α1-174 and α2-173, and 
forms, galactosylhydroxylysine (G-Hyl) and glucosylgalactosylhydroxylysine (GG-Hyl) in 
type I collagen of MC. In these sites, GG-Hyl was significantly diminished with concomitant 
increase in the G-Hyl in Sh collagen compared to the control. From the cultured cell/matrix 
layers, the formation of covalent intermolecular cross-links in Sh clones was significantly 
lower when compared to the controls. When the cell/matrix layers from the clones were 
subjected to in vitro incubation up to 4 weeks, the decreases in immature collagen cross-links 
in Sh clones were slower than those of controls but the increases in mature cross-links were 
relatively comparable to controls. Collagen fibers from the Sh clones were thinner than those 
of the controls, as seen from picrosirius red staining. By in vitro mineralization assay, the 
onset of mineralized nodules formation in the Sh clones was significantly delayed when 
compared to MC and EV. These results indicate that the LH3-mediated glucosylation 
occurring at the specific molecular loci in the type I collagen molecule, plays critical roles in 
controlling collagen cross-linking, matrix organization and mineralization. 
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Introduction 
O-linked glycosylation of Hyl residues has long been known to be unique post-
translational modifications for collagens and proteins with collagenous sequences (5,150). 
They are modulated by collagen glycosyltransferases, the enzymes that transfer the 
carbohydrate units (D-galactose and D-glucose) O-glycosidically to the hydroxyl group of 
specific hydroxylysine (Hyl) residues. This group of enzymes comprise of hydroxylysyl 
galactosyltransferase (GT) (EC 2.4.1.50) and galactosylhydroxylysyl glucosyltransferase 
(GGT) (EC 2.4.1.66) which form galactosylhydroxylysine (G-Hyl) and 
glucosylgalactosylhydroxylysine (GG-Hyl) respectively (186). To date, the GT activity is 
shown to be modulated by the multifunctional enzyme lysyl hydroxylase 3 (LH3)(79-80), 
despite some conflicting data, and the most recently identified glycosyltransferase family 25 
domain 1 and 2 (GLT25D1 and D2)(81). The GGT activity, on the other hand, is mainly 
catalyzed by LH3 (69-70,79,108,184) (reviewed in section 1.6.2).  
In normal conditions, studies have shown that the level of glycosylation varies among 
different collagen types (5,150), different functional regions in the same tissue (124,151), 
different tissues, and developmental stages (103,127,152-153,161). Previous studies have 
reported the identification of specific glycosylation sites in type I collagen from various 
species (113-117) (reviewed in Table 1.2). To date, the biological functions of glycosylated 
Hyl residues have not been clearly defined, however studies have demonstrated their 
associations in collagen fibrillogenesis (8-10,187), susceptibility of collagen to enzymatic 
digestion (9), collagen cross-links formation (38,118,123,168), and collagen-matrix proteins 
interactions (148-149) (reviewed in section 1.6.3-1.6.8). Moreover, it has been shown to have 
a significant contribution towards the quality of extracellular matrices synthesis, organization 
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and maturation, as seen from several connective tissue disorders in which different levels of 
collagen glycosylations were observed (100-101,154-159,163) (reviewed in section 1.7). 
In mineralized tissue (e.g. bone or dentin), type I collagen serves as a scaffold for 
mineral deposition by which the extent, types of post-translational modifications, and the 
molecular packing of collagen molecules were shown to have significant effects. Analyses of 
rat bone have demonstrated the differences between cortical and trabecular bone in terms of 
the types and degree of post-translational modifications and mineralization (124,151,188). 
Previous report from our laboratory, by Pornprasertsuk et al, has shown that by 
overexpressing LH2b (the telopeptidyl LH) in MC cells, there is a significant increase in the 
formation of Hyl
ald
-derived cross-links, formation of collagen fibrils with smaller diameter 
and a delayed mineralization (49). On the other hand, underexpression of decorin (DCN), the 
negative regulator of collagen fibrillogenesis, in MC cells resulted in the formation of 
collagen fibrils with irregular shapes and larger diameter along with an enhanced rate of 
mineral deposition (17,48) (reviewed in section 1.5). 
From Study I (Chapter 3), we have shown that the major function of LH3 protein for 
bone type I collagen is to transfer glucose units to G-Hyl residues and that alteration in the 
level of glucosylation significantly affected the kinetics of in vitro collagen fibril formation. 
To further elucidate the biological significance of the LH3-mediated glucosylation, type I 
collagen from MC and one of the previously established Sh clones will be subjected to mass 
spectrometry analysis for the identification of specific glycosylation sites and forms (GG-Hyl 
and G-Hyl). Moreover, the effects of lowered level of type I collagen glucosylation, from 
LH3 suppression, on cross-links formation and maturation, extracellular matrix organization, 
maturation and mineralization, would be investigated. 
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Experimental Procedures 
 
Cell culture, generation of Sh clones and purification of type I collagen 
The pSilencer2.1-U6/neo-Plod3 construct encoding the short hairpin sequence 
targeting Plod3 was generated, and the MC3T3-E1cell-derived clones stably suppressing 
Plod3 (Sh clones) were obtained as previously described (Chapter 3). MC cells and the 
previously characterized empty vector transfected clone (EV clone: transfected with the 
original pSilencer2.1-U6/neo encoding a hairpin siRNA sequence not found in any genome 
database) were used as controls. The suppressions of Plod3 were verified by quantitative real 
time PCR and the levels of LH3 protein were assessed by Western blotting or 
immunoprecipitation followed by Western blotting with anti-LH3 antibody. Type I collagen 
purified from the Sh clones and controls were characterized for their collagen glycosylation 
profiles and fibril formation kinetics (Chapter 3). The three Sh clones (Sh1-1, Sh1-2, and 
Sh1-3) and their purified type I collagens, reported previously will be further characterized in 
this study. 
 
Identification of the specific Hyl glycosylation sites and forms by mass spectrometry 
Proteolysis and SDS-PAGE separation. Purified type I collagen (5 µg) was dissolved 
in sample loading buffer and denatured at 95˚C for 10 minutes. The α1 and α2 chains were 
separated by SDS-PAGE on 4-12% Bis-Tris pre-cast gels (Invitrogen, Carlsbad, CA) for 1 
hour at 200 V, 100 mA and 10 W. Following staining with Coomasie Simply Blue, the 
protein bands were excised and subjected to automated in-gel digestion with trypsin over 
night at 37˚C, using a Progest robot digester (Genomic Solutions, Harbor, MI). Alternatively, 
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purified type I collagen (10 µg) was dissolved in 25 mM ammonium bicarbonate, pH 7.6, 
and digested in presence of α-chymotrypsin (enzyme:substrate ratio of  1: 20), over night at 
25˚C. The enzymatic mixture was separated by SDS-PAGE as described, followed by 
excision of the bands and automated in-gel digestion with trypsin. The samples were stored 
at -80° C until further use. 
 
UPLC-nanoESI-QTof MS. The collagen proteolytic mixtures were analyzed by 
LC/MS on a Waters-Micromass Q-Tof Premier mass spectrometer equipped with a 
nanoAcquity UPLC system (Waters, Milford, MA). Analyses were performed on a 3 μm, 
100 μm × 100 mm, Atlantis dC18 column (Waters, Milford, MA), using a flow rate of 300 
nL/min. A C18 trapping column (180 μm × 20 mm) with 5 μm particle size (Waters, Milford, 
MA) was positioned in-line of the analytical column and upstream of a micro-tee union used 
both as a vent for trapping and as a liquid junction. Trapping was performed for 3 min at 5 
μL/min flow rate, using the initial solvent composition. A 4 μL aliquot of the digest sample 
was injected onto the column. Peptides were eluted by using a linear gradient from 98% 
solvent A (0.1% formic acid in water (v/v)) and 2% solvent B (0.1% formic acid in 
acetonitrile (v/v)) to 40% solvent B over 90 minutes. Mass spectrometer settings for the MS 
analysis were: capillary voltage of 3.2 kV, cone voltage of 20 V, collision energy of 5.0 V 
and source temperature of 80° C. Mass spectra were acquired over the mass range 200 – 
2000 Da. For calibration, an orthogonal reference spray (LockSpray) of a solution of Glu1-
Fibrinopeptide B (500 fmol/μL) in water/acetonitrile 80:20 (v/v) and 0.1% formic acid, 
having a reference mass of 785.8496 (2+) was used. 
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LC-nanoChip-ESI ion trap MS. The analyses were performed using an Agilent 6340  
XCT Ultra Ion Trap (Santa Clara, CA) equipped with an HPLC Chip Cube MS interface, an 
Agilent 1100 1200 nanoHPLC and an electron transfer dissociation module. Ion trap-MS/MS 
analyses were performed as follows: 20 µL injections of the tryptic digests dissolved in 0.1% 
formic acid were loaded onto a 40 nL enrichment column followed by a 43 mm x 75 µm 
analytical column, packed with ZORBAX 300SB C18 particles (Agilent, Santa Clara, CA). 
Linear gradients of 3-50% (0.1% FA) were performed over 50 min at a flow rate of 500 
nL/min. The parameter settings for positive ion ESI-MS were as follows: capillary voltage – 
2000 V, end plate offset – 500 V, capillary exit – 180 V, nebulizer – 2 psi, dry gas – 4 L/min, 
dry gas temperature – 325 °C. For MS/MS (ETD or CID), automated data dependent 
acquisitions of the six most abundant ions were employed. For CID, the fragmentation 
amplitude was 0.80 V. For ETD analyses, the accumulation time of the fluoranthene gas was 
40 msec, and the reaction time was typically 100 or 150 ms. 
 
Expressions of lysyl oxidase family 
MC cells, EV and Sh clones were plated at a density of 2x10
5
 cells/35mm dish and 
after 48 hours, total RNA was extracted with TRIzol reagent (Invitrogen), and two µg of total 
RNA was converted into cDNA by using the Omniscript Reverse Transcriptase kit (Qiagen, 
Valencia, CA, USA). Quantitative real-time PCR was performed using the sequence specific 
primer for lysyl oxidase (LOX) (LOX; ABI assay number: Mm00495386_m1), LOXL1 
(LOXL1; Mm00241410_m1), LOXL2 (LOXL2; Mm00804740_m1), LOXL3 (LOXL3; 
Mm00442953_m1), LOXL4 (LOXL4; Mm00446385_m1). The reactions were prepared and 
analyzed in triplicates by the ABI Prism 7000 Sequence detection system (Applied 
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Biosystems, Foster city, CA, USA). The mRNA expression level of LH3 relative to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; ABI assay number 4308313) was 
analyzed by the 2
-ΔΔCT
 method (171). 
 
Collagen cross-links analysis 
MC, Sh (Sh1-1, 1-2 and 1- 3), and EV clones were cultured in α-MEM, 10% FBS, 
and 50 µg/ml ascorbic acid. After 2 weeks of culture, cells/matrices were scraped, thoroughly 
washed with PBS and cold de-ionized distilled water (DDW), and lyophilized. The samples 
were prepared for collagen cross-links analysis as previously described (173). Briefly, two 
mg of dried samples was suspended in 0.15 M N-trismethyl-2-aminoethanesulfonic acid and 
0.05 M Tris-HCl buffer (pH 7.4) and reduced with standardized NaB
3
H4. The reduced 
samples were hydrolyzed with 6N HCl in vacuo, flushed with N2, incubated at 110°C for 22 
hrs, dried, dissolved in distilled water, and filtered. An aliquot of the hydrolysate was 
subjected to amino acid analysis to determine Hyp content, and the hydrolysates with known 
amounts of Hyp were analyzed for cross-links on a cation-exchange column (AA-911; 
Transgenomic., Omaha, NE, USA) linked to a fluorescence detector (FP1520; Jasco 
Spectroscopic, Tokyo, Japan) and a liquid scintillation analyzer (500TR series; Packard 
Instrument, Meriden, CT, USA) as described previously (2). The cross-link precursor 
aldehydes (i.e., Hyl
ald
 and Lys
ald
), the major reducible cross-links (i.e., 
dehydrodihydroxylysinonorleucine/its ketoamine [deH-DHLNL], 
dehydrohydroxylysinonorleucine/its ketoamine [deH-HLNL]), and  dehydrohistidino-
hydroxymerodesmosine (deH-HHMD) were analyzed as their reduced forms, that is, 
dihydroxynorleucine (DHNL), hydroxynorleucine (HNL), DHLNL, HLNL, and HHMD, 
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respectively. The level of mature non-reducible cross-links, pyridinoline (Pyr) and 
deoxypyridinoline (d-Pyr) were measured with the fluorescence detector and quantified 
based on the available standard. All cross-links and precursor aldehydes were quantified as 
moles per mole of collagen (33).  
The glycosylated immature bivalent cross-links (GG-DHLNL, G-DHLNL, GG-
HLNL or G-HLNL) were analyzed by subjecting the reduced cell/matrix layer to base 
hydrolysis with 2N NaOH, in sealed polypropylene tubes flushed with N2 gas, and incubated 
at 110°C for 22 hours. The hydrolysate was acidified to a ~pH 3 with 2N HCl, and filtered.  
Without the available glycosylated immature cross-links standards, the MC base hydrolysate 
was applied to the cation-exchange column mentioned above. The separation of the potential 
reducible, glycosylated and the known non-glycosylated immature cross-links were 
observed. Brief acid hydrolysis of the base hydrolysate with 6N HCl at 110°C for 20 minutes 
was performed to cleave the sugar attachments for further identification of the types and 
elution time of the different cross-links species (GG-,G-, or un-modified). Next, an aliquot of 
the reduced cell/matrix base hydrolysate of the Sh clones and controls were separated as 
mentioned above. The amounts of the glycosylated and non-glycosylated immature reducible 
cross-links were quantified and shown in percentages. The amount as moles / mole collagen 
cannot be calculated solely from base hydrolysate analysis, since Hyp is partially degraded in 
the base hydrolysis condition, thus the levels of total cross-links from acid hydrolysis is 
needed. As for the mature cross-links, Pyr and its glycosylated forms are unstable under the 
base hydrolysis condition, rendering its quantification not feasible.  
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In vitro collagen cross-links maturation assay 
The lyophilized cell/matrix layers collected at 2 weeks from the Sh clones and 
controls, MC and EV, were each weighed at 2 mg/time point, for 4 time points (Wk0, Wk1, 
Wk2 and Wk4). The cell/matrices, except the ones assigned for Wk0, were incubated in air, 
in 1ml PBS supplemented with 0.7mM βAPN (ß-aminopropionitrile), two drops of toluene 
and placed in a 37°C incubator, avoiding light exposure. At the end of each time point, the 
samples were removed from the incubator, centrifuged, and lyophilized. When the samples 
from all the time points were collected, they were reduced with standardized NaB
3
H4, acid 
hydrolyzed and analyzed for the levels of immature reducible cross-links (DHLNL and 
HLNL) and mature non-reducible cross-links (Pyr and d-Pyr) as described above. 
 
Picrosirius red staining 
The organization and maturation of type I collagen produced by the controls and Sh 
clones were assessed by Picrosirius Red Staining (189-190).  The cells and clones were 
plated at the density of 2X10
5
 cells onto coverslips placed in 35mm dishes and cultured in the 
medium supplemented with 50μg/ml ascorbic acid for 4 weeks after confluence. The 
cell/matrix layers were then washed twice with PBS, fixed with 10% formalin for 30 
minutes, washed twice with PBS and incubated with 2ml of Picrosirius Red reagent (0.1% 
Sirius Red in saturated picric acid; Electron Microscopy Science, Hatfield, PA, USA) at 
room temperature for 30 minutes.  The stained matrices were rinsed with DDW and followed 
by overnight wash at room temperature. The coverslips were lifted from the dishes and 
dipped sequentially in increasing concentration of ethanol (50-60-70-90-100%) and xylene. 
The coverslips with the attached matrices were embedded onto the glass slide and left to dry 
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at room temperature for overnight. The samples were observed under a polarized light 
microscope (Olympus America Inc., Pittsburgh, PA, USA) and photographed. 
 
In vitro mineralization assay 
MC cells, EV, and Sh clones were plated at the density of 2X10
5
cells/35 mm dishes 
and cultured in α-MEM containing 10% FBS, 100 units/ml penicillin, and 100μg/ml 
streptomycin. When confluence is reached, the cells were maintained in the mineralization 
medium containing 50μg/ml ascorbic acid and 2mM β-glycerophosphate, and cultured up to 
4 weeks. At the end of each week, the cell/matrices layers from each sample were washed 
with PBS twice, fixed with 100% methanol and stained with 1% Alizarin Red S (Sigma-
Aldrich, St Louis, MO, USA), which binds to calcium in the mineralized nodules deposited. 
The rate and the extent of mineral deposition among the clones with varying levels of LH3 
enzyme were compared. 
 
Statistical analyses 
Statistical analyses were performed using Jmp®8.0 software (SAS Institute Inc., 
Cary, NC, USA). Statistical differences were determined by Kruskal-Wallis one-way 
analysis of variance and means comparison by Student’s t test. The data were presented as 
means ± SD and a p value less than 0.05 was considered significant. 
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Results 
 
Identification of specific glycosylation sites by mass spectrometry 
For glycopeptide analysis, the α1(I) and α2(I) chains were separated by SDS-PAGE, 
digested with trypsin and analyzed without further enrichment by HPLC-chip nano ESI-ion 
trap MS. The MS and MS/MS spectra were acquired using data dependent acquisition of the 
six most abundant precursor ions. The glycopeptides [76-90] containing the glycosylated 
residue Hyl 87 were observed as triply protonated ions of m/z 558.7 and 612.7, 
corresponding to glycoforms G-Hyl and GG-Hyl, respectively. The extracted ion 
chromatograms (EIC) of the two ions in the α1 tryptic digest isolated from the MC and Sh1 
collagen are shown in Figure 4.1A and 4.1C. The averaged mass spectra over the 
chromatographic elution time of glycopeptides [76-90] observed in the MC and Sh1 collagen 
sample are shown in Figure 4.1B and 4.1D. The major glycopeptide observed in the MC α1 
tryptic digest as the ion of m/z 612.7 (3+), was assigned to peptide [76-90] containing GG-
Hyl and oxidized methionine. The glycoform containing G-Hyl, at m/z 558.7 (3+), was 
observed with lower relative abundance (Figure 4.1B). In contrast, in the α1 chain isolated 
from the Sh1 collagen, the most abundant glycoform attached at residue 87 was assigned to 
G-Hyl, while GG-Hyl was found considerably decreased compared to MC (Figure 4.1C and 
4.1D). Structural characterization of these glycopeptide ions by electron transfer dissociation 
(ETD) confirmed the assignment based on the presence of fragment ions arising from 
cleavage of the N-Cα bond retaining the glycan moiety (Figure 4.2 A-B). In the full scan 
mass spectrum, additional ions arising from the loss of the N-terminal residues Gly-Leu from 
the glycosylated peptide [76-90] were observed as peaks  at m/z 556.0 (3+) and 502.1 (3+),  
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and were assigned to residues [78-90] modified with GG-Hyl and G-Hyl, respectively. 
Furthermore, the ion of m/z 448.1(3+), arising from the neutral loss of galactose from the 
peptide fragment [78-90], was observed in the MS spectrum as well. The three triply 
protonated ions of m/z 556.0, 502.0 and 448.1 are, most likely, formed by in-source 
decomposition of the glycosylated species [76-90], because they have identical 
chromatographic elution profiles with the intact glycopeptides observed as m/z 612.7 and 
558.7. However, overall in MC collagen, the glycopeptides [76-90] containing GG-Hyl are 
more abundant than that containing G-Hyl while in Sh collagen, the majority of the  
 
 
Figure 4.1) Mass spectrometry characterization of MC and Sh1 α1(I) glycopeptides [76-90]. 
Extracted ion chromatograms (EIC) of ions m/z 612.7 (3+) and 558.7 (3+) in the tryptic digest of 
collagen α1(I)-chain isolated from (A.) MC collagen, and (C.) Sh1 collagen, showing the relative 
abundance of glycopeptides [76-90] containing G-Hyl and GG-Hyl. Full scan mass spectra averaged 
over the chromatographic elution time of glycopeptide ions of m/z 612.7 and 558.7 in (B.) MC 
collagen, and (D.) Sh1 collagen. The ions indicated with asterisks represent in-source decomposition 
products arising from (*) peptide bond cleavage between residues Leu-Hyp at the N-terminus, and (**) 
glycosydic bond cleavage. The data was obtained by LC-chip nano ESI ion trap. 
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glycopeptides [76-90] contain G-Hyl. The relative changes in the glycosylation pattern of site 
Hyl 87 observed in Sh1 collagen can be attributable to the suppression of LH3.  
From MC collagen, Lys residue 87 on the α2 chain was exclusively observed 
modified by lysine hydroxylation in peptide [76-87] as the doubly protonated molecule of 
m/z 619.81. The identity of the peptide [76-87] was confirmed by MS/MS (Figure 4.3). No 
species containing unmodified (α2-Lys 87) or glycosylated α2-Hyl 87 was observed. Similar 
modification profile was seen at α2-87 of Sh1 collagen. It is noteworthy that this residue was  
 
 
 
Figure 4.2) Structural characterization of α1(I) glycopeptides [76-90]. 
Electron transfer dissociation (ETD) spectra acquired on the ion trap of the 
ions of (A.) m/z 612.7 (3+), and (B.) m/z 558.7 (3+), corresponding to the 
α1(I)  glycopeptides [76-90] containing GG-Hyl, and G-Hyl respectively.  
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found glycosylated in collagen isolated from bovine bone (data not shown). However, two 
amino acid substitutions proximal to Hyl 87 in the mouse α2 chain, Ile89Val and Arg90Lys, 
may be responsible for the observed differences in glycosylation status of α2-Hyl 87.  
Early pioneer work in the area of collagen glycosylation documented the existence of 
additional glycosylation sites in type I collagen isolated from different sources (116-117) 
(reviewed in Table 1.2). In the LC-MS/MS analysis of MC-collagen digested with α-
chymotrypsin and trypsin on the QTof Premier, glycosylated structures contained at Hyl 174 
on α1, and Hyl 173 on α2 chains were observed. Residue 174 on MC α1 chain was observed 
in peptides [145-174] and [145-183], the latter containing one miscleavage at Hyl 174. The 
deconvoluted mass spectrum over the chromatographic time window in which the molecular  
 
Figure 4.3) Structural characterization of α2(I) peptide [76-87]. Collision induced 
dissociation (CID) spectrum of the ion of m/z 619.81 (2+), assigned to the α2(I) peptide 
[76-87], containing hydroxyproline as the C-terminal residue. The spectrum was 
obtained on the QTof Premier with a collision energy ramp from 25 to 30 V. 
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species containing residue 174 eluted, is shown in Figure 4.4A. The extended molecular 
microheterogeneity of the species bearing residue 174 is attributable to lysine hydroxylation 
and partial glycosylation of hydroxylysine. The major modification observed at residue 174 
is represented by lysine hydroxylation, while glycosylation of Hyl 174 is relatively low.   
However, within the glycosylated structures, G-Hyl ([M+H]
+
obs.:  3577.379 Da) was 
found with higher relative abundance than GG-Hyl ([M+H]
+ 
obs:  3739.449 Da), in contrast 
to the glycosylation pattern observed for MC α1-Hyl 87. The structural characterization of 
glycopeptides [145-183] was confirmed by collision induced dissociation on the QTof (data  
 
Figure 4.4) Mass spectrometry characterization of modifications at  α1(I)-174 and  α2(I)-173 in 
MC and Sh1 collagen. Deconvoluted mass spectra showing the site-specific microheterogeneity 
derived from lysine hydroxylation and hydroxylysine glycosylation of : (i) residue 174 on α1(I) chain 
in (A.) MC collagen, and (B.) Sh1 collagen, and (ii), residue 173 on α2(I) in (C.) MC collagen, and 
(D.) Sh1 collagen. The amino acid sequence of the observed tryptic peptides are indicated at the top 
of each spectrum. The data was acquired on a Waters QTof Premier instrument. 
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not shown). Additional heterogeneity of peptides [145-183] was due to hydroxylation of Pro 
155, representing, most likely, 3-hydroxyproline. In the Sh1 collagen, isolated from the LH3-
suppresed clone, similar heterogeneity of lysine hydroxylation to the wild type was observed. 
However, the only glycosylated structure detected at Hyl 174 was G-Hyl, while GG-Hyl was 
present at the noise level (Figure 4.4B). This again indicates that the major function of LH3 
is to transfer glucose residues to the G-Hyl residues in collagen.  
The residue homologous to α1-Lys 174 is residue 173 on the α2 chain, observed in 
peptides [144-173] and [144-191]. The deconvoluted mass spectrum over the 
chromatographic time window in which the molecular species containing residue 173 eluted, 
is shown in Figure 4.4C, for the MC collagen. Similar to residue α1-174, Lys 173 was 
observed in peptide [141-173] both unmodified ([M+H]
+ 
obs: 2589.075 Da), as well as 
hydroxylated ([M+H]
+ obs:  2605.081 Da). In contrast to α1-Hyl 174, α2-Hyl 173 was found 
to have higher glycosylation occupancy, as the relative levels of glycosylated Hyl are higher 
compared to those of free Hyl. The glycosylated peptides [144-191] were observed as G-Hyl 
([M+H]
+ 
obs:
+
 4363.827 Da) and GG-Hyl [M+H]
+ 
obs: 4525.916 Da). Their identities were 
confirmed by MS/MS (data not shown). Drastic changes in the glycosylation status of site 
173 on α2 were found in the Sh1 collagen isolated from the LH3-suppresed clone (Figure 
4.4D), because no glycopeptide ion corresponding to [144-191] bearing GG-Hyl was 
detected. 
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By comparing the amino acid sequences of the α1 and α2 chains, exclusively at the 
regions of the identified glycosylation sites, among different species, it is apparent that in the 
α1 chain there is a high degree of sequence homology around the Lys residue (K) found to be 
glycosylated (residue 87 and 174) (Figure 4.5A). The sequence comparison of α2 chain, on 
the contrary, showed amino acid differences adjacent to the Lys residue 87 of the mouse 
sequence (GFKGVK vs GFKGIR) but not at residue 173 (Figure 4.5B). The differences 
shown may indicate the requirement of specific sequences for the galactosyltransferase 
reaction. 
 
Collagen cross-links analysis 
The collagen cross-links produced by MC cells and the Sh clones at 2 weeks culture 
composed mainly of immature reducible bivalent crosslinks (DHLNL and HLNL), and in a 
small amount mature trivalent cross-links (Pyr).  Deoxypyridinoline (d-Pyr) was not detected 
in the cultures of MC cells or EV and Sh clones. The actual amounts of DHLNL, HLNL, Pyr, 
and the cross-links forming aldehydes (total aldehydes = DHLNL + HLNL + 2XPyr) are 
depicted in Table 4.1. From the LH3-suppressed Sh clones, it is evident that the less  
 
 
Figure 4.5) Protein sequence alignment 
of α1(I) and α2(I) chains from various 
species. Sequence alignment at the 
identified glycosylation sites, α1-87, α1-
174, α2-87 and α2-173, among mouse, 
rat, human and bovine. Note the sequence 
differences at residues 89 and 90 of 
mouse α2 chain comparing to the other 
species. 
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glucosylated type I collagen showed a decrease in the level of cross-links formation. The 
decrease of DHLNL, formed from telopeptide Hyl
ald
 and helical Hyl residue, was statistically 
significant (p < 0.05), while the level of HLNL was less affected. Moreover, the levels of Pyr 
from the Sh clones were also found to be significantly lower (p < 0.05). Altogether, the levels 
of total Ald (DHLNL + HLNL + 2XPyr) in the Sh clones showed a decreasing trend when 
compared to the controls, even though not statistically significant. However, it is apparent 
that the significant changes are seen with the immature cross-link, DHLNL and its 
maturation product, Pyr. 
 
Expressions of LOX and its isoforms 
The lowered levels of total aldehydes, hence decreased collagen cross-links formation 
observed in the Sh clones may be contributed by the effect of LH3 suppression on the lysyl 
oxidase (LOX) enzymes, catalyzing the Lys and Hyl aldehydes formation which are the 
precursors of intermolecular cross-links. However, real-time PCR analysis showed a slight 
upregulation of LOX and its isoforms (LOXL1, LOXL3 and LOXL4) expressions in the Sh  
Table 4.1 The levels of immature reducible cross-links (DHLNL and HLNL) and mature non-
reducible cross-links (Pyr) from MC cells, EV and Sh clones. (moles/mole collagen) 
 
Values represent mean (SD) from three independent experiments. *, significantly different from 
controls MC and EV (p < 0.05). Total Ald = DHLNL + HLNL + 2XPyr, DHLNL, 
dihydroxylysinonorleucine; HLNL, hydroxylysinonorleucine; Pyr, pyridinoline; and Ald, aldehydes.  
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clones compared to the controls (Figure 4.6), rendering this cause unlikely. The expression of 
LOXL2 was not detected in both the controls and Sh clones. Since the amount of LOX 
enzymes are not lowered, thus it could be suggested that their functions may be impaired. 
 
Glycosylated cross-links analysis 
Glycosylation of the immature bivalent cross-links were analyzed from the base 
hydrolysate of the reduced cell/matrix layer of MC cells and the EV and Sh clones. The 
identities of the potential glycosylated cross-links peaks were indirectly confirmed by brief 
acid hydrolysis of the base hydrolysate to observe the conversion from the GG- or G- 
modified form into the unmodified cross-links i.e. DHLNL or HLNL. In Figure 4.7A, the 
chromatogram of cross-links analysis from MC base hydrolysate showed the separation of 
the unmodified DHLNL and HLNL (based on the available standards) and a major peak 
eluted at 26 minutes, possibly the glycosylated cross-links (123,191). The result from the 
acid hydrolysis of the MC base hydrolysate is shown in Figure 4.7B.  There was a significant 
decrease of the peak eluted at 26 minutes with simultaneous increases in the peaks at 33 
minutes and 47 minutes, which is the known elution time for unmodified DHLNL,  
 
Figure 4.6) mRNA expression 
of LOX family (LOX, LOXL1, 
LOXL3, and LOXL4) relative 
to Col1A2, in the Sh clones 
(Sh1-1,-2,and -3) and controls 
(MC and EV). LOX, lysyl 
oxidase; LOXL, lysyl oxidase 
like. Error bar indicates mean ± 
SD of triplicate analyses. 
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suggesting the occurrence of the conversions. From this result, GG-DHLNL and G-DHLNL 
could possibly be assigned to the peaks at 26 and 33 minutes respectively. As for HLNL, no 
significant alteration was observed in the base followed by brief acid hydrolysis condition, 
suggesting that they may be originated from Lys
ald
 X non-glycosylated Hyl or Hyl
ald
 X Lys.  
Unfortunately, glycosylated Pyr cannot be analyzed by this method since it was reported that 
base hydrolysis could destroy at least 90% of the 3-hydroxypyridinium cross-links (Pyr and 
d-Pyr)(192).  
Table 4.2 shows the quantification of GG-DHLNL, G-DHLNL and free DHLNL 
from the MC, EV and Sh clones from two independent experiments. The levels are shown in 
moles/mole collagen, calculated from the percentages of each DHLNL species (GG-, G-, and 
free DHLNL) obtained from the analyses of base hydrolysates and the total DHLNL from 
acid hydrolysates. From Table 4.1, we have shown that the level of total DHLNL from the Sh 
clones are significantly lower comparing to the controls (p < 0.05). By quantifying the levels 
of different DHLNL species, it is evident from the Sh clones that, there is a decrease in the  
 
Figure 4.7) Ion-exchange 
chromatogram of potential glycosylated 
immature reducible cross-links. A. 
Chromatogram of base hydrolysate of 
reduced MC cell/matrix layer showed a 
high abundance of radioactive compound 
eluted around 26 min. B. Chromatogram 
of the brief acid hydrolysis of the above 
base hydrolysate showing a significant 
decrease in the abundance of the peak 
eluted at 26 min with simultaneous 
increase of the peaks at 33 and free 
DHLNL at 47 min.  
GG-: glucosylgalactosyl-, G-: galactosyl-, DHLNL: dihydroxylysinonorleucine, HLNL: 
hydroxylysinonorleucine. 
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level of GG-DHLNL, comparing to MC and EV, with concomitant increase in the level of G-
DHLNL when comparing to MC. The levels of free DHLNL in the Sh clones are lower when 
compared to MC and EV. The difference between the two batches of culture was observed 
exclusively in EV as shown by the high standard deviation. For that reason, extra sets of 
cultures are being analyzed for confirmation of the glycosylated DHLNL profiles. 
From the MS analysis shown above, only one cross-linking site was shown to be fully 
glycosylated, α1-Hyl 87, therefore, the glycosylated cross-linking profile shown in Table 4.2 
would most likely be derived from this particular site. The MS analysis of Sh1 collagen 
demonstrated a significant change in the site occupancy from GG-Hyl to G-Hyl residue (GG-
Hyl < G-Hyl) (Figure 4.1).  Surprisingly, from the cross-links analysis of the Sh clones, 
higher abundance of GG-DHLNL compared to G-DHLNL (GG-DHLNL > G-DHLNL) was 
observed (Table 4.2), suggesting that at α1-Hyl 87, the GG-Hyl residue may be the 
preferential form for the formation of immature bivalent cross-links, rather than G-Hyl. Free 
DHLNL, the major form found, could be derived from α2-Hyl 87 (mainly Hyl) or potentially 
the other cross-linking site residue 930, at which Hyl glycosylation has never been reported. 
 
Table 4.2 Levels of glycosylated and free DHLNL. (moles/mole collagen)  
 Values represent mean (SD) from two independent experiments. GG-: 
glucosylgalactosyl-, G-: galactosyl-, DHLNL: dihydroxylysinonorleucine. 
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In vitro cross-links maturation assay 
It is well established that Pyr is the maturational product from the condensation 
reaction between two DHLNL residues (34,36), resulting in a trivalent cross-link formed 
between Hyl
ald
 X Hyl
ald
 X Hyl. To directly measure the rate of cross-links maturation without 
the constant formation of new immature cross-links, we have utilized the in vitro cross-links 
maturation assay previously used in several reports (26,29,193-194) with some 
modifications. Figure 4.8 shows the changes in the levels of DHLNL and Pyr over time    
(Wk 0-1-2-4). After the first week of incubation of MC and EV cell/matrices, there is a fast 
decrease in the level of DHLNL which gradually decline thereafter. At the same time, 
interestingly, DHLNL in all the Sh clones were decreased at a slower rate, when compared to 
the controls. As for the formation of Pyr, it is apparent that in both the controls and Sh clones  
 
Figure 4.8) In vitro cross-links maturation assay. 3µg of lyophilized cell matrix layers from the 
culture of MC, EV and the Sh clones were incubated (see methods). At week 1, 2 and 4 of incubation, 
the samples were reduced with NaB
3
H4 and analyzed for the levels of immature reducible (DHLNL 
and HLNL) and mature non-reducible (Pyr) cross-links. DHLNL levels changes are shown with solid 
lines while those of Pyr (P_ ) are shown with dashed lines.  
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the increase of Pyr is clearly unproportional to the decrease of DHLNL. Two independent 
incubations were performed and the results were of the same trend. This unidentified loss of 
DHLNL (not forming Pyr) has been observed in previous studies (27-28) and to date the 
mechanism is still unknown.  
Table 4.3 demonstrates the total level decrease of DHLNL (ΔDHLNL) and increase 
of Pyr (ΔPyr) during the 4 weeks incubation. The levels of Pyr-forming DHLNL (ΔPyrX2) 
were calculated and found that they were lower than the levels decline of DHLNL 
(ΔDHLNL).  In bone, it was previously shown that for immature bivalent cross-links, GG-
DHLNL is the predominant form over G-DHLNL, while for the mature trivalent cross-links, 
interestingly, G-Pyr is the major form and GG-Pyr is undetectable (reviewed in Table 1.1).  
So far the fate of GG-DHLNL in the maturation process is still unknown. From these 
evidences, it is possible that the unidentified loss of total DHLNL observed in the cross-links 
maturation assay shown in this (Figure 4.8) and previous studies (28) may be attributed to the 
unknown fate of GG-DHLNL. Moreover, the different levels of GG-DHLNL between the 
controls and Sh clones may be a possible cause of the different rate decrease of DHLNL 
Table 4.3 The level changes of Pyr and DHLNL during 4 weeks incubation and potential 
mechanism (moles/mole collagen) 
 
Value represent mean (SD) from two independent incubations. ΔPyr: total pyridinoline formation, 
ΔDHLNL: total dihydroxylysinonorleucine decrease, GG-: glucosylgalactosyl-. 
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shown in Figure 4.8. In Table 4.3, when the levels of GG-DHLNL at Wk0 (non-incubated) 
were added to the levels of Pyr-forming DHLNL during 4 wks incubation (ΔPyrX2) from 
each sample (Sum), the outcome was relatively close to the total level decrease of DHLNL 
(ΔDHLNL) in both the Sh clones and controls. Altogether, the results shown here may 
suggest the possibility that mainly G-DHLNL and free DHLNL are the preferred forms to 
mature into G-Pyr and free Pyr respectively, which is consistent with previous reports 
showing mainly the presence of G-Pyr and free Pyr in bone tissue (38,121-122). The 
mechanism behind the disappearance of GG-DHLNL is yet to be determined. 
 
Collagen matrix organization and maturation 
The effect of lowered level of type I collagen glycosylation, from LH3 suppression, 
on collagen matrix organization and maturation was assessed by Picrosirius red staining. The 
Sh clones and the controls were cultured with supplementation of 50µg/ml ascorbic acid for 
4 weeks followed by the staining of the matrices with 1% picrosirius red and observed under 
a polarized light microscope. As shown in Figure 4.9, the collagen matrix laid down by MC 
cells and EV clone is organized, mature and thick, as observed by the intense red staining of 
the collagen fibers. On the other hand, the collagen fibers of the Sh clones are thinner and 
less matured, as seen from the yellowish-orange staining. Two independent experiments were 
performed and analyzed at both 2 and 4 weeks time points, and the results were of similar 
trend (data not shown). 
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In vitro matrix mineralization assay 
The results of in vitro mineralization assay, by Alizarin Red Staining, are shown in 
Figure 4.10. In the controls, MC and EV, the formation of mineralized nodules, is already 
observed at 2-3 weeks of culture and the number and size of nodules are gradually increases 
overtime. On the contrary, matrix mineralization in the Sh clones is markedly delayed. At 4 
weeks, the cultures of Sh1-1 and Sh1-2 clones show almost no mineralized nodules 
formation, while a few is observed in Sh1-3 clone. Three independent experiments were 
performed with similar results observed. 
 
 
 
 
 
Figure 4.9) Picrosirius red staining. MC cells, EV and Sh clones were cultured for 4 weeks and 
the matrices were stained with picrosirius red observed under polarized light microscope. One 
representative image of each cell type is shown at 10X magnification.  MC, MC3T3-E1 cells; EV 
clone, empty vector transfected clone; Sh clones, single cell-derived clones stably transfected with 
short hairpin containing plasmid targeting Plod3. 
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Figure 4.10) In vitro mineralization assay. MC cells, EV and Sh clones were cultured in 
mineralization medium for 1, 2, 3 and 4 weeks. At the end of each week, the cell/matrices were 
stained with Alizarin Red S and the mineralized nodules were observed. MC, MC3T3-E1 cells; EV 
clone, empty vector transfected clone; Sh clones, single cell-derived clones stably transfected with 
short hairpin containing plasmid targeting Plod3; Wk, Week. 
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Discussion 
 
Type I collagen is a member of the fibrillar collagens with uniquely low levels of Hyl 
glycosylation (127,150). Sequencing of collagen and identifying its specific glycosylation 
sites have been studied in collagen from various tissues, species and reported in several 
publications over the 45-year span (reviewed in Table 1.2). The specific glycosylation sites 
in type I collagen identified, in most species, were those at residues 87 and 174 in α1 chain 
and residues 87 and 174 in α2 chain (113-117). In Chapter 3, we have shown that 
suppression of LH3 in mouse osteoblasts resulted in a decrease in the total levels of GG-Hyl 
with a simultaneous increase in the levels of G-Hyl in type I collagen, as determined by 
amino acid analysis. In the present study, we have employed high performance liquid 
chromatography – tandem mass spectrometry analyses of the glycopeptides formed by 
proteolytic degradation to characterize site specific glycosylation changes in type I collagen. 
One challenging aspect of collagen glycosylation analysis by mass spectrometry was derived 
from the fact that several glycosylated Hyl residues were contained in peptides larger than 
3500 Da, which rendered these difficult to observe on the ion trap.  However, from the MS 
analyses of the tryptic peptides, three Hyl residues were found glycosylated in MC collagen, 
i.e. Hyl 87 and Hyl 174 on α1, and Hyl 173 on α2 chain. In peptide [76-90] the glycosylated 
Hyl 87 was not cleaved by trypsin, suggesting that the substrate specificity is drastically 
altered by the presence of the carbohydrate units, which is in agreement with previous studies 
(195). Moreover, the absence of the cleavage at α1-Hyl 87 may also indicate that this site is 
fully glycosylated since enzymatic cleavage C-terminal of hydroxylysine was still observed 
in non-glycosylated peptides. While the major glycoform of the fully glycosylated α1-Hyl 87 
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in MC was determined as GG-Hyl, residues α1-Hyl 174 and α2-Hyl 173 were observed 
partially occupied, with the major glycoform determined as G-Hyl. In the LH3-suppressed 
clone, GG-Hyl was solely detected, with lower abundance, on α1-Hyl 87, while for α1-Lys 
174 and α2-Lys 173 this glycoform was only present at the noise level.  These sites were 
consistent with those identified previously (113-117) despite the numbering difference 
among species at residue 174 or 173 of α2 chain. Unlike earlier reports (reviewed in table 
1.2), residue α2-87 in MC collagen was mainly detected as non-glycosylated Hyl. This result 
and the differences in the amino acids sequence in this particular region between mouse and 
the other species, may implicate sequence specific requirements for the galactosyltransferase 
enzyme function. Our results demonstrated, possibly for the first time, the specific molecular 
loci and forms of Hyl glycosylation in mouse bone collagen. These site-specific 
glycosylation changes, from LH3 suppression, may help explain the potential role of each 
glycosylated Hyl in the collagen physiology. In Sh1 collagen, the detection of GG-Hyl at α1-
Hyl 87, but not at any other sites, indicates that G-Hyl 87 represents the primary substrate for 
the glucosylation activity of LH3. 
Collagen cross-linking has been known to be essential for the mechanical stability of 
the extracellular matrix of the connective tissues. In mineralized tissues, there is a uniquely 
lower abundance of mature trivalent cross-links, Pyr and d-Pyr, and higher levels of 
immature bivalent cross-links, DHLNL and HLNL. Besides, Lys
ald
 derived cross-links are 
rarely observed, which indicates a high degree of telopeptidyl Hyl hydroxylation (196). In 
type I collagen, the two major cross-linking sites (residues 87 and 930) in the helical region 
of the α chains have been extensively studied and characterized (197-198).  For residue 930, 
to date and to our best knowledge, there has been no direct evidence identifying the Hyl 
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glycosylation at this position. On the contrary, previous reports have shown that the residue 
87-derived DHLNL (both from α1 or α2 chain) in bone were found to be mainly di-
glycosylated (118-120,168). Also from these sites, a few HLNL (Lys
ald
 X Hyl) was detected 
and found to be glycosylated especially in the α2-derived HLNL (120) (reviewed in Table 
1.1). Previously, Robins et al have shown that, in bone, 70% of HLNL is derived from Hyl
ald
 
X Lys (199), hence no glycosylation. In this study, we have shown from mouse bone 
collagen that, the only cross-linking site to be glycosylated is α1-87 but not α2-87. 
Altogether, it could be suggested that the presence of glycosylated HLNL in mouse bone 
collagen would be very minimal, if any. As for the mature trivalent cross-links, in the MC 
cell culture system, only Pyr is present not d-Pyr, indicating that the helical Lys residues 
involved in the formation of pyridinium cross-links are fully hydroxylated. 
The results from our study demonstrated that decreased G-Hyl glucosylation, 
mediated by LH3 suppression, result in a significant decrease in the formation of total 
aldehydes from the Sh clones, when compared to the controls, MC and EV.  Interestingly, the 
expressions of LOX family (LOX, LOXL1, LOXL3, and LOXL4), the enzymes catalyzing 
the formation of cross-link precursors (Lys
ald
 or Hyl
ald
) in the Sh clones were slightly 
upregulated compared to controls. Without the effect on the quantity of the LOX enzymes, 
the decreased formation of cross-links may result from their impaired functions. It was 
reported that LOX is more active towards quarter-staggered, native collagen fibrils and was 
suggested that the intermolecular interaction between collagen molecules are important for 
the enzyme activity (20). Studies have shown that the binding sites for LOX in type I 
collagen are in the triple helical region (21), potentially in the area with highly conserved 
sequences (Hyl-Gly-His-Arg), the cross-linking site residue 87, where it can catalyze the 
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formation of Lys or Hyl aldehydes in the telopeptides of the adjacent collagen molecule 
(reviewed in (22)). Collectively, there is a high possibility that the decrease in G-Hyl 
glucosylation at the major cross-linking site (α1-87) of the Sh collagen could affect the 
binding and/or function of the LOX enzymes, since it may alter the surface physico-chemical 
characteristics of the collagen molecules.  
 In this study, we have demonstrated the levels of glycosylated DHLNL (GG-DHLNL 
and G-DHLNL), potentially derived exclusively from α1-87, from the cultures of MC, EV 
and the Sh clones. Interestingly, in the Sh clones, the levels of GG-DHLNL are higher than 
G-DHLNL, while MS analysis at α1-87 showed a reverse in the relative abundance of GG-
Hyl to G-Hyl (GG-Hyl < G-Hyl). Previous reports have also shown the higher levels of GG-
DHLNL over G-DHLNL in bovine (119) and human (120) bone (reviewed in Table 1.1). 
Altogether, these data may indicate that at this particular site, GG-Hyl could be the preferred 
form for bivalent cross-links formation.  
In regards to the maturation of immature bivalent into mature trivalent cross-links 
(DHLNL into Pyr, the major forms in bone), the most adopted mechanism is the spontaneous 
condensation reaction between two DHLNL resulting in the links between two Hyl
ald 
and one 
Hyl residue (34). By incubating bone collagen in vitro, faster decrease was observed in the 
level of DHLNL compared to HLNL, especially in the first 2 wks of incubation. The authors 
have suggested that the difference in the glycosylation content between them may have 
contributed to the different rate of disappearance during the maturation process (27). 
Moreover, Eyre et al had analyzed the level of immature and mature cross-links in human 
bone tissue of different ages, and showed a fast decrease in the level immature bivalent cross-
links while the level of Pyr formation was unproportionally low. The data shown represented 
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the cross-links maturation in vivo, and prompted speculations of novel maturational products 
(28). In this study, in order to study the role of collagen glycosylation in cross-link 
maturation, we have employed the in vitro incubation assay and showed that, during the 
course of incubation there was a faster decrease in DHLNL of the controls, MC and EV, 
when compared to the Sh clones. We have speculated that the unproportional decline of total 
DHLNL may be from the loss of GG-DHLNL to an unknown mechanism. This speculation 
is based on the following observations: - 1. The decrease rate of DHLNL appeared to 
correlate with the level of GG-DHLNL (faster decrease with higher levels of GG-DHLNL), 
2.  In bone, GG-DHLNL is the predominant glycosylated immature cross-links, while G-Pyr 
is the major mature form present (38,121-122)(reviewed in Table 1.1), 3. From Table 4.3 of 
in vitro incubation study, when the amount of GG-DHLNL is added to the level of Pyr-
forming DHLNL, the outcome is relatively close to the total level decrease of DHLNL. 
Further studies are thus warranted to uncover the mechanism and significance of this 
unidentified loss of DHLNL. 
The organization and maturation of collagenous matrix of the Sh clones, exhibiting 
lowered level of GG-Hyl, has been characterized by picrosirius red staining. In comparison 
to the controls, MC and EV, the Sh clones laid down less matured and thinner collagen 
fibers. This result is not in accordance with our previous study (Chapter 3) and others (8-
10,187) showing that collagen with lower level of glycosylation form fibrils with larger 
diameter, in vitro. This discrepancy may result from the fact that the in vitro fibril formation 
assay performed only account for the difference in the intrinsic factor in the collagen 
molecules between the Sh clones and controls, i.e. the levels of Hyl glucosylation. In the cell 
culture system, on the contrary, other potential extrinsic factors for collagen fibrillogenesis, 
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such as other minor collagen types (reviewed in (18)) or proteoglycans (12-13,200) may have 
contributed to the formation of thinner collagen fibers in the Sh clones. It also has been 
shown previously that type I collagen with lower levels of glycosylation was less deposited 
into the matrix (101,125), and was more susceptible to mammalian collagenase digestion (9). 
Consistent with former reports, our data provide indications that collagen molecules with 
optimal levels of modifications would be deposited into the matrix and stabilized by the 
formation of cross-links while collagen with lowered level of glucosylation (↓GG-Hyl and 
↑G-Hyl), were less cross-linked and possibly susceptible to collagenase digestion. 
Consequently, the impaired matrices formed by the less glucosylated type I collagen, from 
the Sh clones, were apparently not a suitable template for the mineralization process, as seen 
from the significant delay in mineralized nodules formation. This data is consistent with our 
previous publications showing that small collagen fibrils are not good templates for mineral 
deposition (48-49).  
In conclusion, by suppressing LH3 in mouse osteoblasts, we have developed a 
valuable tool to study the biological significance of the LH3-mediated glucosylation of G-
Hyl in type I collagen. The glycosylation sites and forms were identified by MS and their 
alterations from LH3 suppression were correlated with the phenotypic changes in cross-links 
formation, extracellular matrix organization and mineralization.  The results shown in our 
study and previous evidences may have indicated the biological roles of the glucose units in 
GG-Hyl residues, at the major cross-linking residue α1-87, in the mechanisms of 
intermolecular cross-links formation and maturation. Firstly, the glucose units appeared to 
have a positive regulatory role in the binding and/or function of LOX enzymes, since 
suppression of glucosylation resulted in a significant decrease in the level of total aldehydes 
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(total cross-links) formation. Secondly, because higher levels of GG-DHLNL were formed 
over G-DHLNL, even from the Sh clones with lower levels of GG-Hyl residues, therefore 
GG-Hyl may be the more preferred form in the formation of DHLNL. Thirdly, for the 
spontaneous conversion of DHLNL into Pyr, since GG-Pyr was barely found in bone 
collagen unlike other tissues (38,121-122), we have proposed that GG-DHLNL was likely 
involved in the rapid decrease of DHLNL observed in the in vitro incubation study. 
However, its fate and the selective condition or mechanism pertaining to specific tissues 
remained to be further investigated. Even so, the results in this study have shown, for the first 
time, the biological significance of the LH3-mediated glucosylation on the quality of type I 
collagen matrix formation and mineralization. 
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Abstract 
Glycosylation of collagens occurs through a series of enzymatic reactions including 
the hydroxylation of helical lysine (Lys) residues, galactosylation of hydroxylysine (Hyl) 
residues and finally, glucosylation of galactosylhydroxylysine (G-Hyl) residues forming 
glucosylgalactosylhydroxylysine (GG-Hyl) residues. We have shown in Chapter 3 that, in 
type I collagen, the multifunctional enzyme lysyl hydroxylase 3 (LH3) mainly catalyzes the 
glucosylation reaction not the Lys hydroxylation or subsequent galactosylation. 
Glycosyltransferase 25 domain 1 and 2 (Glt25d1 and 2) are a recently identified novel family 
of enzymes that may function as collagen galactosyltransferase. In our previous study 
(Chaptor 3), we reported that Glt25d1 was the only isoform expressed in mouse osteoblast 
cell line MC3T3-E1 (MC). In this study, in order to elucidate the function of Glt25d1 in type 
I collagen, we generated MC cell-derived clones stably suppressing Glt25d1 by use of short 
hairpin RNA technology and analyzed the collagen synthesized. The results showed that the 
levels of both G-Hyl and GG-Hyl in type I collagen from the Sh clones were significantly 
decreased in comparison to those of controls. The data indicates that Glt25d1 is the major 
collagen galactosyltransferase for bone type I collagen.  
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Introduction 
Collagens and proteins containing the collagenous triplet repeats (Gly-X-Y), were 
shown to possess unique post-translational modifications including the hydroxylation of 
proline (Pro), and lysine (Lys) and the glycosylation of hydroxylysine (Hyl) (5). The 
biological significance of glycosylated Hyl in fibrillar collagens is still unclear however it 
was shown to be associated with the control of collagen fibrillogenesis (8-11,112), cross-
linking (38,118,121-124,168), remodeling (126-133) , and collagen-cell interaction (148-
149) (reviewed in section 1.6.3-1.6.8). Besides, it is shown to be essential for the biosynthesis 
and secretion of highly glycosylated non-fibrillar collagens (69-70,99). For collagen-like 
proteins, the glycosylated Hyl residues in adiponectin and mannose-binding lectin (MBL) 
appeared to be involved in the oligomerization and secretion of the proteins (reviewed in 
(81)).  
Hydroxylysine glycosylation is modulated by the group of enzymes known as 
collagen glycosyltransferases which transfer the carbohydrate units (D-galactose, or D-
glucose) O-glycosidically to hydroxyl group of specific Hyl residues. The reactions involve 
two essential steps, firstly, the galactosylation of Hyl by hydroxylysyl galactosyltransferase 
(GT) (EC 2.4.1.50) forming galactosylhydroxylysine (G-Hyl), and secondly, the 
glucosylation of G-Hyl by galactosylhydroxylysyl glucosyltransferase (GGT) (EC 2.4.1.66) 
forming glucosylgalactosylhydroxylysine (GG-Hyl) (103). These enzymes were previously 
characterized from whole chick embryo until a decade ago when these functions were 
discovered in the multifunctional collagen modifying enzyme, lysyl hydroxylase 3 (LH3) 
(79-80,108). Characterization of LH3 deficient mice showed an embryonic lethal phenotype 
at E9.5 due to the impaired type IV and VI collagen biosynthesis and the severity of the 
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phenotype showed a significant correlation to the level of GGT activity (69-70,99) (reviewed 
in section 1.6.2).  
As for the GT activity of LH3, the data has been conflicting (70,79-81) and the 
biological significance was unclear until most recently, a novel family of collagen 
galactosyltransferase enzyme encoded by the GLT25D1 and GLT25D2 has been discovered 
and characterized, showing the capabilities of transferring galactose units, but not glucose, to 
collagens and MBL (81). Unlike LH3, GLT25D1 and GLT25D2, was shown to be strictly 
maintained in the ER by the ER retention motif, RDEL (81,111). Among them, GLT25D1 
exhibited broad expression in fetal and adult human tissues, and was suggested to be the 
main collagen galactosyltransferase enzyme, while GLT25D2 was only detected in a few cell 
types (81). So, there is a high possibility that Hyl galactosylation would be mainly modulated 
by GLT25D1 and subsequent glucosylation by LH3.  
From our previous studies (Chapter 3 and 4) in mouse osteoblast cell-line (MC3T3-
E1 (MC)), we have demonstrated that for type I collagen, LH3 mainly catalyzes the final 
transfer of glucose units to G-Hyl and thus leaving the regulation of the intermediate step, 
galactosylation of Hyl, unclear. However, since then we have also found that in MC cells, 
Glt25d1 is the only isoform expressed, not Glt25d2. This had led us to hypothesize that 
Glt25d1 may galactosylate Hyl residues while LH3 glucosylates G-Hyl residues. In order to 
elucidate the functional involvement of Glt25d1 in the sequential glycosylation process of 
Hyl in bone type I collagen, we have employed the short hairpin RNA technology, 
successfully used for the suppression of LH3 in MC cells (Chapter 3). Single cell-derived 
clones stably suppressing Glt25d1 were generated and their synthesized type I collagen 
analyzed for the levels of Hyl glycosylations. The results shown here, though preliminary, 
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are supportive of the hypothesis that Glt25d1 modulates the GT activity in bone type I 
collagen.  
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Experimental Procedures 
 
Cell Lines and Culture Conditions 
MC3T3-E1 subclone #4 (MC), a well characterized nontransformed mouse 
osteoblast-like cell line (170) was purchased from American Type Culture Collection (CRL-
2593). The cells were grown in α-MEM (Invitrogen, Carlsbad, CA, USA) containing 10% 
FBS (Invitrogen) and supplemented with 100 U/ml penicillin G sodium, 100 g/ml 
streptomycin sulfate. The cells were cultured in a 5% CO2 atmosphere at 37ºC and the 
medium was changed twice a week. 
 
Generation of short hairpin expressing plasmid targeting Glt25d1 
The short hairpin expression plasmids were generated by the same method described 
in detail in Chapter 3. Briefly, the target sequences for suppression of mouse Glt25d1 were 
designed (si#1 GGAATAATGAGCAGGTTAA [start position 1891], si#2 
AGGCAGAGGTGCAAATGTA [985], si#3 TGTCAGAATACAAGAGTCA [1762]) and 
converted into short hairpin oligonucleotide sequences specific for pSilencer2.1 vector. The 
two complimentary 55-mer oligonucleotides for each target were ordered, annealed then 
ligated into the pSilencer2.1-U6/neo vector (Ambion, Austin, TX, USA), linearized with 
restriction enzymes digestion, and transformed into bacteria competent cells. The clones with 
100% nucleotide sequence accuracy (Eton Bioscience, Durham, NC, USA) for each target 
(G_Sh1, 2 and 3) were selected and tested for their suppression efficiency by transient 
transfection into MC cells using FuGENE6 transfection reagent (Roche, Indianapolis, IN, 
USA). The non-transfected MC cells and those transfected with the original pSilencer2.1-
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U6/neo plasmid (EV; encoding a hairpin siRNA sequence not found in any genome database) 
were used as controls. After 48 hours, total RNA was extracted, converted into cDNA by 
using the Omniscript Reverse Transcriptase kit (Qiagen, Valencia, CA, USA). Quantitative 
real-time PCR was performed using the sequence specific primer for Glt25d1 (Glt25d1; 
Mm00600638_m1). The reactions were prepared and analyzed in triplicates by the ABI 
Prism 7000 Sequence detection system (Applied Biosystems, Foster city, CA, USA). The 
mRNA expression level of Glt25d1 relative to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH; ABI assay number 4308313) was analyzed by the 2
-ΔΔCT
 method (171).  The 
suppression efficiency among the different ShRNA target sites was then compared in 
percentage relative to the controls. 
 
Generation and characterization of MC single cell-derived clones stably suppressing 
Glt25d1 (G_Sh clones) 
MC cells were transfected with the selected pSilencer2.1-U6/neo-G_Sh plasmid by 
using FuGENE6 transfection reagent (Roche), and isolation of single cell-derived clones 
stably suppressing Glt25d1 was performed as described in Chapter 3.  The selected G_Sh 
clones were then characterized by comparing the level of Glt25d1 expression to those of the 
EV clone (generated and characterized in Chapter 3) and the non-transfected MC cells, by 
using quantitative real-time PCR. Three to six Sh clones with different levels of Glt25d1 
suppression were then characterized for their effects on the mRNA expression of LH1 
(Plod1; ABI assay number: Mm00599925_m1), LH2 (Plod2; Mm00478767_m1), LH3 
(Plod3; Mm00478798_m1), and type I collagen α2 chain (Col1A2; Mm00483888_m1).  
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Purification of type I collagen 
Type I collagen without telopeptides was purified from the 2-week cell/matrix layers 
of MC cells, EV and G_Sh clones with the same methods, described in Chapter 3.  
 
Quantification of GG-Hyl, G-Hyl and Free Hyl 
Lyophilized collagen samples from MC cells, EV and G_Sh clones were acid and 
base hydrolyzed, and analyzed by amino acid analysis as described in detail in Chapter 3.  
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Results 
 
Generation of clones stably suppressing Glt25d1 
The pSilencer2.1-U6/neo-G_Sh plasmids (G_Sh1, 2 and 3) were transiently 
transfected into MC cells and the expressions of Glt25d1 and Col1A2 were analyzed by 
quantitative real-time PCR. From the cells transfected with the short hairpin constructs 
(G_Sh1, 2 and 3), the expression of Glt25d1 relative to GAPDH was 36%, 39% and 35% 
respectively, of 100% expression in MC non-transfected cells. The expressions of Glt25d1 
relative to Col1A2 are shown in Figure 5.1. Transfection of the G_Sh1 construct resulted in a 
lowered level of Glt25d1 relative to Col1A2, while the G_Sh2 and 3 constructs showed off 
target effects on Col1A2 expression. The effects led to higher expression levels of Glt25d1 
relative to Col1A2, when compared to the controls, MC and EV.  Since our aim is to analyze 
the effects of gene manipulation on the levels of collagen post-translational modification, the 
relative expression of the gene to Col1A2 is an important factor to be taken into 
consideration. Therefore the target sequence #1 (G_Sh 1), with the least off target effect on  
 
Figure 5.1) Gene expression of Glt25d1 from transient transfection of short hairpin constructs 
targeting Glt25d1. pSilencer2.1-U6/neo-G_Sh1, 2, 3 and EV plasmids were individually transfected 
into MC cells. After 48 hours of culture, real time PCR was performed to determine the suppression 
levels of Glt25d1 and the expression of Col1A2. The Glt25d1 mRNA expression was normalized to 
the expression of Col1A2.  
106 
 
 
Col1A2, was selected for further generation of single cell-derived clones stably suppressing 
Glt25d1 by constant selection with G418.  
 
Characterization of G_Sh1-derived clones stably suppressing Glt25d1 
Several clones were initially isolated and characterized based on their cell 
morphology and growth pattern compared to controls, MC and EV. Three representative 
clones (G_Sh1-1, -2, and -3) showing similar growth patterns to the controls, were selected 
for further phenotypic characterization. Real-time PCR analysis was performed to assess the 
levels of Glt25d1 and the effects of its suppression on the expression of Plod family (Plod1, 
Plod2 and Plod3 encoding LH1, LH2 and LH3 respectively), relative to Col1A2. In 
comparison to MC non-transfected control (100%), the expression of Glt25d1in the G_Sh 1-
1,-2 and -3 clones were 16%, 45% and 37% respectively. Figure 5.2 demonstrated the effect  
 
Figure 5.2) Gene expression of Glt25d1 and Plod family in single cell-derived clones stably 
suppressing Glt25d1 (G_Sh clones) After 48 hours of culture, real time PCR was performed to 
determine the suppression levels of Glt25d1 in the single cell-derived G_Sh clones and its potential 
effects on Plod1, Plod2 and Plod3 expression. The mRNA expression was normalized to the 
expression of Col1A2.  
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of Glt25d1 suppression on the levels of Plod family. In the G_Sh clones, the expression of 
Plod1 was ~1.5-2 fold higher, while the expression of Plod2 was essentially comparable to 
MC and EV. On the contrary, Plod3 was upregulated in the G_Sh as well as in the EV 
clones, ranging from 1.1-2.3 fold increase, suggesting the effect of transfection as previously 
discussed in Chapter 3.  
 
Quantification of GG-Hyl, G-Hyl and Free Hyl  
Type I collagen without telopeptides purified from MC cells, EV and G_Sh clones 
(G_Sh1-1, -2 and -3) was subjected to acid and base hydrolysis and analyzed by the newly 
established amino acid analysis program described in Chapter 3. Figure 5.3 shows the levels 
of total Hyl and each Hyl species (GG-Hyl, G-Hyl and free Hyl) expressed as residues/mol 
collagen. The levels of total Hyl in all the G_Sh collagens are slightly higher than those of 
MC and EV. The observation in G_Sh collagen of significant decrease in the level of Hyl 
glycosylation (GG-Hyl + G-Hyl) with a simultaneous increase in the level of free Hyl 
 
Figure 5.3) The modification levels of Hyl residues in the purified type I collagen synthesized by 
G_Sh1 clones and controls. The levels of total Hyl and each Hyl species (GG-Hyl, G-Hyl and free 
Hyl) in the purified type I collagen synthesized by G_Sh1 clones and controls, MC and EV. The 
levels are shown as residues/mol collagen. 
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indicates the decreased transfer of galactose units to Hyl residues. The reduced levels of G-
Hyl residues in the G_Sh collagens were further glucosylated by the endogenous LH3 and 
resulted in the formation of GG-Hyl residues at levels lower than those of MC and EV. In the 
G_Sh clones, the levels of GG-Hyl residues appeared to be correlated to the expression levels 
of LH3 gene, however in EV, the level of GG-Hyl was slightly lower than in MC, despite the 
higher LH3 expression. Potentially, the lower Glt25d1 expression in EV may contribute to 
the lower levels of G-Hyl residues to function as substrates for the GGT activity of LH3. 
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Discussion 
Prior to the discovery of the novel collagen galactosyltransferase enzymes, GLT25D1 
and GLT25D2, the biological significance of the GT activity identified in LH3 has been in 
question. Conflicting results from several studies have been reported showing low level of 
activity (79-80) or undetectable (70,81). In discovering the novel enzymes, Schegg et al have 
characterized the enzymatic functions by means of GT and GGT activity assays and showed 
that GLT25D1 and D2 were capable of transferring the galactose units to collagen substrates 
and mannose-binding lectin, while LH3 was strictly a GGT enzyme (81). In Chapter 3, we 
have shown that, firstly, LH3 mainly modulates the GGT but not the GT activity for type I 
collagen. Secondly, we have also shown that Glt25d1 is the only isoform expressed in mouse 
osteoblasts which may suggest its potential role as a GT enzyme.  
Therefore, in this preliminary study, we have attempted to uncover the biological 
function of Glt25d1 for type I collagen. Type I collagen purified from the single cell-derived 
clones stably suppressing Glt25d1 was shown to be, overall, less glycosylated with 
concomitant increase in the level of free Hyl. This clearly indicates that by suppressing 
Glt25d1, the transfer of galactose units to Hyl was impaired; hence the higher levels of free 
Hyl and less G-Hyl substrate for the GGT activity of LH3. Moreover, this is another 
confirmation of the insignificance of the GT activity of LH3, since upregulation of Plod3 
expression was observed in the G_Sh clones; however the galactosylation level was still very 
low. Unfortunately, the Glt25d1 protein levels in the controls and G_Sh clones could not be 
effectively investigated due to lack of an antibody with good sensitivity and specificity to the 
protein. Several attempts to optimize the Western blot condition using two commercially 
available Glt25d1 antibodies have so far been unsuccessful. Further phenotypic 
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characterization of MC cell-derived G_Sh clones in regards to collagen fibrillogenesis, cross-
linking profile, extracellular matrix formation and mineralization are still ongoing. 
In conclusion, the preliminary results shown here are in good support of our 
hypothesis that in bone type I collagen, Glt25d1 catalyzes the transfer of galactose units to 
Hyl residues and subsequently, LH3 modulates the final transfer of glucose units to G-Hyl 
residues. To date, our studies would be the first to elucidate the enzymatic regulatory 
mechanisms of Hyl galactosylation and subsequent glucosylation in type I collagen from 
osteoblasts culture by direct measurement of the G-Hyl and GG-Hyl respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 6 
 
Concluding Remarks 
 
For type I collagen, until now, the enzymatic controls of the formation and the 
biological functions of the glycosylated Hyl (G-Hyl and GG-Hyl) residues had remained 
elusive. The GT and GGT activities were shown to be modulated by LH3 (79-80) until the 
recent identification of GLT25D1 and D2 as novel collagen GT enzymes (81). To uncover 
their roles for type I collagen, we have suppressed the LH3 encoding Plod3 and Glt25d1 (the 
only isoform expressed) in mouse osteoblast cell line, MC3T3-E1 (MC) and generated single 
cell-derived clones (Sh and G_Sh clones respectively). By characterizing the clones, we have 
discovered the following: 
1. The major function of LH3 is to transfer glucose units to G-Hyl residues in the α chains 
of bone type I collagen as determined by amino acid analyses of collagen from the Sh 
clones and the HPLC-based glycosyltransferase activity assays using purified 
recombinant LH3-V5/His tagged protein. 
2. The less glucosylated type I collagen, from the Sh clones, showed different in vitro fibril 
formation kinetics when compared to the controls, MC and EV. 
3. By utilizing mass spectrometry (MS), specific molecular loci of Hyl glycosylation and 
forms (G-Hyl and GG-Hyl) in the α chains of MC collagen were identified at residues 
α1-87, α1-174 and α2-173. In the collagen from the LH3-suppressed clone (Sh1 
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4. collagen), the presence of GG-Hyl was significantly diminished while G-Hyl was the 
major form observed; ultimately confirming the major role of LH3 as a 
glucosyltransferase enzyme. 
5. From collagen cross-links analyses, the levels of total cross-links (total aldehydes) 
formation were significantly lower in the Sh clones, despite the higher expression of 
LOX enzymes. It may suggest that by suppressing LH3 the less glucosylated collagen 
may not be a good substrate for the LOX enzymes; hence the lower levels of aldehydes. 
6. The levels of total glycosylated immature bivalent cross-links (mainly DHLNL) in the Sh 
clones were significantly lower than those in the controls, with higher levels of GG-
DHLNL over G-DHLNL unlike the higher levels of G-Hyl over GG-Hyl at α1-87 
observed in the MS analysis of Sh collagen. These data may indicate that, at this major 
cross-linking site, GG-Hyl is the preferred form for DHLNL formation. 
7. From in vitro cross-links maturation study, there was a faster decline in the levels of total 
DHLNL in the controls than in the Sh clones while the formation of Pyr are overall 
unproportionally low. The difference in the levels of glucosylation between the controls 
and Sh clones, along with previous reports showing only the existence of G-Pyr in bone 
(38,121-122), may point to the possibility that GG-DHLNL could be involved in the 
unidentified loss of total DHLNL, hence the different rate observed between the Sh 
clones and controls.  
8. Thin collagen fibers were formed in the cultures of Sh clone suppressing LH3, when 
compared to the controls, as shown by picrosirius red staining. In addition, these thin 
collagen fibers may not be suitable templates for mineral deposition since significant 
delay in the mineralized nodules formation was observed from Alizarin Red S staining. 
113 
 
These phenomena may result from the possibility that collagen with lower levels of 
glucosylation may be less stabilized in the extracellular matrix, since the levels of cross-
links in the Sh clones are significantly lower, or it could be subjected to enzymatic 
degradation digestion (9).  
9. Glt25d1 is the major galactosyltransferase enzyme for type I collagen, shown from the 
characterization of collagen from G_Sh clones by amino acid analysis.  
Collectively, the findings from this study clearly demonstrated that, for bone type I 
collagen, the galactosylation of Hyl residues is modulated be Glt25d1 and the subsequent 
glucosylation of G-Hyl is catalyzed by LH3. The glucose units in the specific GG-Hyl 
residues appeared to have positive regulatory roles in the formation of intermolecular cross-
links and normal collagen template for the mineralization process. These findings may have 
given new insights to the biological significance of type I collagen O-glycosylation in bone 
physiology. 
The association of bone type I collagen overglycosylation with the poor bone quality 
phenotype has been reported in several human osteogenic disorders such as osteogenesis 
imperfecta (OI) (156,160), post-menopausal osteoporosis (155,158,165-166), osteosarcoma 
and osteofibrous dysplasia (159), but the mechanisms are only partially understood.  
Mutations in the α chains of type I collagen, in some subtypes of OI, impaired the folding of 
α chains into triple helix and higher levels of post-translational modifications were observed 
(reviewed in (201).  Moreover, impaired function of the collagen chaperone complex, 
P3H/CRTAP/CyPB complex, is shown to be the cause of recessive OIs with overmodified 
collagen and normal COL1A1 and COL1A2 sequences (202). However, the mechanism 
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behind the association between overmodified/overglycosylated collagen and poor bone 
quality is still unclear.  
In order to elucidate the effect of collagen overglycosylation on the mechanism of 
mineralization, based on what we have known from this study, future experiments can be 
perfomed, in vitro, to simulate the overglycosylation phenotype in bone type I collagen by 
utilizing the gain-of-function approach in MC cell. By overexpressing Glt25d1, it is likely 
that the increased level of G-Hyl residues will be subjected to further glucosylation by the 
potent LH3, endogenously expressed. Alternatively, a combination of LH1 and Glt25d1 
overexpression may result in a higher degree of glycosylation in collagen, comparing to 
transfection of Glt25d1 alone, since total Hyl in the helical region may be increased from the 
higher level of LH1. If successfully generated, these overexpressed clones showing 
overglycosylated collagen may be subjected to in vitro mineralization assay and/or in vivo 
transplantation model (17,172) to evaluate the mineralized nodules or the quality of the bone 
tissue formed. Eventually, the thorough understanding of the regulatory mechanisms of the 
biosynthesis of type I collagen and its formation of extracellular matrix, the basic structure in 
bone tissue, may lead to the development of effective interventions to improve the quality of 
bone for the patients. 
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